Cover page
Cover page - shares | 6 Months Ended | |
Aug. 31, 2024 | Oct. 03, 2024 | |
Entity Addresses [Line Items] | ||
Document Type | 10-Q | |
Document Quarterly Report | true | |
Document Period End Date | Aug. 31, 2024 | |
Document Transition Report | false | |
Entity File Number | 001-14669 | |
Entity Registrant Name | HELEN OF TROY LIMITED | |
Entity Incorporation, State or Country Code | D0 | |
Entity Tax Identification Number | 74-2692550 | |
Entity Address, Address Line One | 1 Helen of Troy Plaza | |
Entity Address, City or Town | El Paso | |
Entity Address, State or Province | TX | |
Entity Address, Postal Zip Code | 79912 | |
City Area Code | 915 | |
Local Phone Number | 225-8000 | |
Title of 12(b) Security | Common Shares, $0.10 par value per share | |
Trading Symbol | HELE | |
Security Exchange Name | NASDAQ | |
Entity Current Reporting Status | Yes | |
Entity Interactive Data Current | Yes | |
Entity Filer Category | Large Accelerated Filer | |
Entity Small Business | false | |
Entity Emerging Growth Company | false | |
Entity Shell Company | false | |
Entity Common Stock, Shares Outstanding | 22,851,622 | |
Entity Central Index Key | 0000916789 | |
Current Fiscal Year End Date | --02-28 | |
Document Fiscal Year Focus | 2025 | |
Document Fiscal Period Focus | Q2 | |
Amendment Flag | false | |
Other Address | ||
Entity Addresses [Line Items] | ||
Entity Address, Address Line One | Clarendon House | |
Entity Address, Address Line Two | 2 Church Street | |
Entity Address, City or Town | Hamilton | |
Entity Address, Country | BM |
Condensed Consolidated Balance
Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands | Aug. 31, 2024 | Feb. 29, 2024 |
Assets, current: | ||
Cash and cash equivalents | $ 20,137 | $ 18,501 |
Receivables, less allowances of $7,438 and $7,481 | 365,675 | 394,536 |
Inventory | 469,625 | 395,995 |
Prepaid expenses and other current assets | 29,909 | 27,012 |
Income taxes receivable | 15,289 | 7,874 |
Total assets, current | 900,635 | 843,918 |
Property and equipment, net of accumulated depreciation of $186,489 and $169,021 | 331,496 | 336,646 |
Goodwill | 1,066,730 | 1,066,730 |
Other intangible assets, net of accumulated amortization of $195,941 and $186,882 | 528,511 | 536,696 |
Operating lease assets | 34,707 | 35,962 |
Deferred tax assets, net | 3,811 | 3,662 |
Other assets | 14,487 | 15,008 |
Total assets | 2,880,377 | 2,838,622 |
Liabilities, current: | ||
Accounts payable | 323,256 | 245,349 |
Accrued expenses and other current liabilities | 163,684 | 181,391 |
Income taxes payable | 13,943 | 17,821 |
Long-term debt, current maturities | 7,813 | 6,250 |
Total liabilities, current | 508,696 | 450,811 |
Long-term debt, excluding current maturities | 705,422 | 659,421 |
Lease liabilities, non-current | 37,056 | 37,262 |
Deferred tax liabilities, net | 49,347 | 41,253 |
Other liabilities, non-current | 12,276 | 12,433 |
Total liabilities | 1,312,797 | 1,201,180 |
Commitments and contingencies | ||
Stockholders' equity: | ||
Cumulative preferred stock, non-voting, $1.00 par. Authorized 2,000,000 shares; none issued | 0 | 0 |
Common stock, $0.10 par. Authorized 50,000,000 shares; 22,814,811 and 23,751,258 shares issued and outstanding | 2,281 | 2,375 |
Additional paid in capital | 355,578 | 348,739 |
Accumulated other comprehensive (loss) income | (1,515) | 2,099 |
Retained earnings | 1,211,236 | 1,284,229 |
Total stockholders' equity | 1,567,580 | 1,637,442 |
Total liabilities and stockholders' equity | $ 2,880,377 | $ 2,838,622 |
Condensed Consolidated Balanc_2
Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - USD ($) $ in Thousands | Aug. 31, 2024 | Feb. 29, 2024 |
Statement of Financial Position [Abstract] | ||
Allowance on receivables | $ 7,438 | $ 7,481 |
Property and equipment, accumulated depreciation | 186,489 | 169,021 |
Other intangible assets, accumulated amortization | $ 195,941 | $ 186,882 |
Cumulative preferred stock, nonvoting, par value (in dollars per share) | $ 1 | $ 1 |
Cumulative preferred stock, non-voting, authorized shares (in shares) | 2,000,000 | 2,000,000 |
Cumulative preferred stock, non-voting, issued shares (in shares) | 0 | 0 |
Common stock, par value (in dollars per share) | $ 0.10 | $ 0.10 |
Common stock, authorized shares (in shares) | 50,000,000 | 50,000,000 |
Common stock, shares issued (in shares) | 22,814,811 | 23,751,258 |
Common stock, shares outstanding (in shares) | 22,814,811 | 23,751,258 |
Condensed Consolidated Statemen
Condensed Consolidated Statements of Income (Unaudited) - USD ($) shares in Thousands, $ in Thousands | 3 Months Ended | 6 Months Ended | ||
Aug. 31, 2024 | Aug. 31, 2023 | Aug. 31, 2024 | Aug. 31, 2023 | |
Income Statement [Abstract] | ||||
Sales revenue, net | $ 474,221 | $ 491,563 | $ 891,068 | $ 966,235 |
Cost of goods sold | 258,151 | 261,910 | 471,919 | 520,951 |
Gross profit | 216,070 | 229,653 | 419,149 | 445,284 |
Selling, general and administrative expense (“SG&A”) | 179,692 | 179,191 | 350,173 | 346,826 |
Restructuring charges | 1,526 | 3,617 | 3,361 | 10,972 |
Operating income | 34,852 | 46,845 | 65,615 | 87,486 |
Non-operating income, net | 170 | 148 | 270 | 285 |
Interest expense | 13,216 | 13,654 | 25,759 | 27,706 |
Income before income tax | 21,806 | 33,339 | 40,126 | 60,065 |
Income tax expense | 4,792 | 5,958 | 16,908 | 10,103 |
Net income | $ 17,014 | $ 27,381 | $ 23,218 | $ 49,962 |
Earnings per share (“EPS”): | ||||
Basic (in dollars per share) | $ 0.75 | $ 1.14 | $ 1 | $ 2.08 |
Diluted (in dollars per share) | $ 0.74 | $ 1.14 | $ 1 | $ 2.07 |
Weighted average shares used in computing EPS: | ||||
Basic (in shares) | 22,814 | 23,918 | 23,169 | 23,984 |
Diluted (in shares) | 22,839 | 24,041 | 23,236 | 24,088 |
Condensed Consolidated Statem_2
Condensed Consolidated Statements of Comprehensive Income (Unaudited) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | ||
Aug. 31, 2024 | Aug. 31, 2023 | Aug. 31, 2024 | Aug. 31, 2023 | |
Statement of Comprehensive Income [Abstract] | ||||
Net income | $ 17,014 | $ 27,381 | $ 23,218 | $ 49,962 |
Other comprehensive (loss) income, net of tax: | ||||
Cash flow hedge activity - interest rate swaps | (3,446) | 2,768 | (2,521) | (324) |
Cash flow hedge activity - foreign currency contracts | (866) | (314) | (1,093) | (937) |
Total other comprehensive (loss) income, net of tax | (4,312) | 2,454 | (3,614) | (1,261) |
Comprehensive income | $ 12,702 | $ 29,835 | $ 19,604 | $ 48,701 |
Condensed Consolidated Statem_3
Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($) shares in Thousands, $ in Thousands | Total | Common Stock | Additional Paid in Capital | Accumulated Other Comprehensive Income | Retained Earnings |
Beginning balance (in shares) at Feb. 28, 2023 | 23,994 | ||||
Beginning balance at Feb. 28, 2023 | $ 1,488,811 | $ 2,399 | $ 317,277 | $ 4,947 | $ 1,164,188 |
Increase (Decrease) in Stockholders' Equity [Roll Forward] | |||||
Net income | 22,581 | 22,581 | |||
Other comprehensive income (loss), net of tax | (3,715) | (3,715) | |||
Exercise of stock options (in shares) | 5 | ||||
Exercise of stock options | 212 | $ 1 | 211 | ||
Issuance and settlement of restricted stock (in shares) | 120 | ||||
Issuance and settlement of restricted stock | 0 | $ 12 | (12) | ||
Issuance of common stock related to stock purchase plan (in shares) | 23 | ||||
Issuance of common stock related to stock purchase plan | 2,168 | $ 2 | 2,166 | ||
Common stock repurchased and retired (in shares) | (45) | ||||
Common stock repurchased and retired | (4,446) | $ (4) | (4,442) | ||
Share-based compensation | 9,297 | 9,297 | |||
Ending balance (in shares) at May. 31, 2023 | 24,097 | ||||
Ending balance at May. 31, 2023 | 1,514,908 | $ 2,410 | 324,497 | 1,232 | 1,186,769 |
Beginning balance (in shares) at Feb. 28, 2023 | 23,994 | ||||
Beginning balance at Feb. 28, 2023 | 1,488,811 | $ 2,399 | 317,277 | 4,947 | 1,164,188 |
Increase (Decrease) in Stockholders' Equity [Roll Forward] | |||||
Other comprehensive income (loss), net of tax | (1,261) | ||||
Ending balance (in shares) at Aug. 31, 2023 | 23,719 | ||||
Ending balance at Aug. 31, 2023 | 1,501,883 | $ 2,372 | 330,227 | 3,686 | 1,165,598 |
Beginning balance (in shares) at May. 31, 2023 | 24,097 | ||||
Beginning balance at May. 31, 2023 | 1,514,908 | $ 2,410 | 324,497 | 1,232 | 1,186,769 |
Increase (Decrease) in Stockholders' Equity [Roll Forward] | |||||
Net income | 27,381 | 27,381 | |||
Other comprehensive income (loss), net of tax | 2,454 | 2,454 | |||
Issuance and settlement of restricted stock (in shares) | 4 | ||||
Issuance and settlement of restricted stock | 0 | 0 | |||
Common stock repurchased and retired (in shares) | (382) | ||||
Common stock repurchased and retired | (50,089) | $ (38) | (1,499) | (48,552) | |
Share-based compensation | 7,229 | 7,229 | |||
Ending balance (in shares) at Aug. 31, 2023 | 23,719 | ||||
Ending balance at Aug. 31, 2023 | 1,501,883 | $ 2,372 | 330,227 | 3,686 | 1,165,598 |
Beginning balance (in shares) at Feb. 29, 2024 | 23,751 | ||||
Beginning balance at Feb. 29, 2024 | 1,637,442 | $ 2,375 | 348,739 | 2,099 | 1,284,229 |
Increase (Decrease) in Stockholders' Equity [Roll Forward] | |||||
Net income | 6,204 | 6,204 | |||
Other comprehensive income (loss), net of tax | 698 | 698 | |||
Exercise of stock options (in shares) | 6 | ||||
Exercise of stock options | 352 | $ 1 | 351 | ||
Issuance and settlement of restricted stock (in shares) | 71 | ||||
Issuance and settlement of restricted stock | 0 | $ 7 | (7) | ||
Issuance of common stock related to stock purchase plan (in shares) | 19 | ||||
Issuance of common stock related to stock purchase plan | 2,006 | $ 2 | 2,004 | ||
Common stock repurchased and retired (in shares) | (1,037) | ||||
Common stock repurchased and retired | (103,035) | $ (104) | (6,720) | (96,211) | |
Share-based compensation | 5,833 | 5,833 | |||
Ending balance (in shares) at May. 31, 2024 | 22,810 | ||||
Ending balance at May. 31, 2024 | 1,549,500 | $ 2,281 | 350,200 | 2,797 | 1,194,222 |
Beginning balance (in shares) at Feb. 29, 2024 | 23,751 | ||||
Beginning balance at Feb. 29, 2024 | 1,637,442 | $ 2,375 | 348,739 | 2,099 | 1,284,229 |
Increase (Decrease) in Stockholders' Equity [Roll Forward] | |||||
Other comprehensive income (loss), net of tax | (3,614) | ||||
Ending balance (in shares) at Aug. 31, 2024 | 22,815 | ||||
Ending balance at Aug. 31, 2024 | 1,567,580 | $ 2,281 | 355,578 | (1,515) | 1,211,236 |
Beginning balance (in shares) at May. 31, 2024 | 22,810 | ||||
Beginning balance at May. 31, 2024 | 1,549,500 | $ 2,281 | 350,200 | 2,797 | 1,194,222 |
Increase (Decrease) in Stockholders' Equity [Roll Forward] | |||||
Net income | 17,014 | 17,014 | |||
Other comprehensive income (loss), net of tax | (4,312) | (4,312) | |||
Issuance and settlement of restricted stock (in shares) | 6 | ||||
Issuance and settlement of restricted stock | 0 | ||||
Common stock repurchased and retired (in shares) | (1) | ||||
Common stock repurchased and retired | (109) | $ 0 | (109) | 0 | |
Share-based compensation | 5,487 | 5,487 | |||
Ending balance (in shares) at Aug. 31, 2024 | 22,815 | ||||
Ending balance at Aug. 31, 2024 | $ 1,567,580 | $ 2,281 | $ 355,578 | $ (1,515) | $ 1,211,236 |
Condensed Consolidated Statem_4
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands | 6 Months Ended | |
Aug. 31, 2024 | Aug. 31, 2023 | |
Cash provided by operating activities: | ||
Net income | $ 23,218 | $ 49,962 |
Adjustments to reconcile net income to net cash provided by operating activities: | ||
Depreciation and amortization | 27,628 | 24,606 |
Amortization of financing costs | 639 | 616 |
Non-cash operating lease expense | 5,840 | 3,941 |
Provision for credit losses | 112 | 3,671 |
Non-cash share-based compensation | 11,320 | 16,526 |
Gain on the sale or disposal of property and equipment | (29) | (246) |
Deferred income taxes and tax credits | 9,039 | 6,845 |
Changes in operating capital: | ||
Receivables | 26,340 | (14,427) |
Inventory | (73,630) | 19,804 |
Prepaid expenses and other current assets | (5,805) | (5,391) |
Other assets and liabilities, net | (441) | (253) |
Accounts payable | 78,922 | 71,990 |
Accrued expenses and other current liabilities | (22,529) | (10,317) |
Accrued income taxes | (10,708) | (9,595) |
Net cash provided by operating activities | 69,916 | 157,732 |
Cash used by investing activities: | ||
Capital and intangible asset expenditures | (14,026) | (20,557) |
Payments for purchases of U.S. Treasury Bills | (1,363) | 0 |
Proceeds from the maturity of U.S. Treasury Bills | 1,249 | 0 |
Proceeds from the sale of property and equipment | 39 | 246 |
Net cash used by investing activities | (14,101) | (20,311) |
Cash used by financing activities: | ||
Proceeds from revolving loans | 509,930 | 261,150 |
Repayment of revolving loans | (459,880) | (348,150) |
Repayment of long-term debt | (3,125) | (3,125) |
Payment of financing costs | (318) | 0 |
Proceeds from share issuances under share-based compensation plans | 2,358 | 2,380 |
Payments for repurchases of common stock | (103,144) | (54,535) |
Net cash used by financing activities | (54,179) | (142,280) |
Net increase (decrease) in cash and cash equivalents | 1,636 | (4,859) |
Cash and cash equivalents, beginning balance | 18,501 | 29,073 |
Cash and cash equivalents, ending balance | 20,137 | 24,214 |
Supplemental non-cash investing activity: | ||
Capital expenditures included in accounts payable and accrued expenses | $ 7,767 | $ 2,790 |
Basis of Presentation and Relat
Basis of Presentation and Related Information | 6 Months Ended |
Aug. 31, 2024 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Basis of Presentation and Related Information | Note 1 - Basis of Presentation and Related Information Corporate Overview The accompanying condensed consolidated financial statements contain all adjustments (consisting of normal recurring adjustments) necessary to present fairly our consolidated financial position as of August 31, 2024 and February 29, 2024, and the results of our consolidated operations for the interim periods presented. We follow the same accounting policies when preparing quarterly financial data as we use for preparing annual data. These statements should be read in conjunction with the consolidated financial statements and the notes included in our latest annual report on Form 10-K for the fiscal year ended February 29, 2024 (“Form 10-K”), and our other reports on file with the Securities and Exchange Commission (the “SEC”). When used in these notes, unless otherwise indicated or the context suggests otherwise, references to “the Company”, “our Company”, “Helen of Troy”, “we”, “us”, or “our” refer to Helen of Troy Limited and its subsidiaries, which are all wholly-owned. We refer to our common shares, par value $0.10 per share, as “common stock.” References to “fiscal” in connection with a numeric year number denotes our fiscal year ending on the last day of February, during the year number listed. References to “the FASB” refer to the Financial Accounting Standards Board. References to “GAAP” refer to accounting principles generally accepted in the United States of America (the “U.S.”). References to “ASU” refer to the codification of GAAP in the Accounting Standards Updates issued by the FASB. References to “ASC” refer to the codification of GAAP in the Accounting Standards Codification issued by the FASB. We incorporated as Helen of Troy Corporation in Texas in 1968 and were reorganized as Helen of Troy Limited in Bermuda in 1994. We are a leading global consumer products company offering creative products and solutions for our customers through a diversified portfolio of brands. Our portfolio of brands include OXO, Hydro Flask, Osprey, Vicks, Braun, Honeywell, PUR, Hot Tools, Drybar, Curlsmith and Revlon, among others. As of August 31, 2024, we operated two reportable segments: Home & Outdoor and Beauty & Wellness. Our Home & Outdoor segment offers a broad range of outstanding world-class brands that help consumers enjoy everyday living inside their homes and outdoors. Our innovative products for home activities include food preparation and storage, cooking, cleaning, organization, and beverage service. Our outdoor performance range, on-the-go food storage, and beverageware includes lifestyle hydration products, coolers and food storage solutions, backpacks, and travel gear. The Beauty & Wellness segment provides consumers with a broad range of outstanding world-class brands for beauty and wellness. In Beauty, we deliver innovation through products such as hair styling appliances, grooming tools, and liquid and aerosol personal care products that help consumers look and feel more beautiful. In Wellness, we are there when you need us most with highly regarded humidifiers, thermometers, water and air purifiers, heaters, and fans. Our business is seasonal due to different calendar events, holidays and seasonal weather and illness patterns. Our fiscal reporting period ends on the last day in February. Historically, our highest sales volume and operating income occur in our third fiscal quarter ending November 30th. We purchase our products from unaffiliated manufacturers, most of which are located in China, Mexico, Vietnam and the U.S. During fiscal 2023, we initiated a global restructuring plan intended to expand operating margins through initiatives designed to improve efficiency and effectiveness and reduce costs (referred to as “Project Pegasus”). See Note 6 for additional information. Principles of Consolidation The accompanying condensed consolidated financial statements are prepared in accordance with GAAP and include all of our subsidiaries. Our condensed consolidated financial statements are prepared in U.S. Dollars. All intercompany balances and transactions are eliminated in consolidation. The preparation of consolidated financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the amounts reported in our condensed consolidated financial statements and accompanying notes. Actual results may differ materially from those estimates. During the second quarter of fiscal 2025, we concluded that a goodwill impairment triggering event had occurred primarily due to a sustained decline in our stock price. Additional factors that contributed to this conclusion included current macroeconomic trends and uncertainty surrounding inflation and high interest rates, which negatively impact consumer disposable income, credit availability, spending and overall consumer confidence, all of which have and may continue to adversely impact our sales, results of operations and cash flows. These factors are applicable to all of our reporting units which resulted in us performing quantitative goodwill impairment testing on all of our reporting units. We considered whether these events and circumstances would affect any other assets and concluded to perform quantitative impairment testing on our indefinite-lived trademark licenses and trade names and our definite-lived trademark licenses, trade names, and customer lists. We performed quantitative impairment testing on our goodwill and intangible assets described above and determined none were impaired. Accordingly, no impairment charges were recorded. For additional information, refer to “Critical Accounting Policies and Estimates” in Item 2., “Management's Discussion and Analysis of Financial Condition and Results of Operations”. |
New Accounting Pronouncements
New Accounting Pronouncements | 6 Months Ended |
Aug. 31, 2024 | |
Accounting Changes and Error Corrections [Abstract] | |
New Accounting Pronouncements | Note 2 - New Accounting Pronouncements There have been no changes in the information provided in our Form 10-K. |
Accrued Expenses and Other Curr
Accrued Expenses and Other Current Liabilities | 6 Months Ended |
Aug. 31, 2024 | |
Payables and Accruals [Abstract] | |
Accrued Expenses and Other Current Liabilities | Note 3 - Accrued Expenses and Other Current Liabilities A summary of accrued expenses and other current liabilities was as follows: (in thousands) August 31, 2024 February 29, 2024 Accrued compensation, benefits and payroll taxes $ 19,740 $ 36,572 Accrued sales discounts and allowances 39,984 37,851 Accrued sales returns 20,910 21,282 Accrued advertising 27,503 29,212 Other 55,547 56,474 Total accrued expenses and other current liabilities $ 163,684 $ 181,391 |
Share-Based Compensation Plans
Share-Based Compensation Plans | 6 Months Ended |
Aug. 31, 2024 | |
Share-Based Payment Arrangement [Abstract] | |
Share-Based Compensation Plans | Note 4 - Share-Based Compensation Plans As part of our compensation structure, we grant share-based compensation awards to certain employees and non-employee members of our Board of Directors during the fiscal year. These awards may be subject to attainment of certain service conditions, performance conditions and/or market conditions. During the first quarter of fiscal 2025, we granted 94,900 service condition awards (“Service Condition Awards”) with a weighted average grant date fair value of $124.37. Additionally, we granted 157,797 performance-based awards during the first quarter of fiscal 2025, of which 94,586 contained performance conditions (“Performance Condition Awards”) and 63,211 contained market conditions (“Market Condition Awards”), with weighted average grant date fair values of $124.37 and $91.19, respectively. Refer to our Form 10-K for further information on the Company's share-based compensation plans. We recorded share-based compensation expense in SG&A as follows: Three Months Ended August 31, Six Months Ended (in thousands) 2024 2023 2024 2023 Directors stock compensation $ 196 $ 196 $ 392 $ 393 Service Condition Awards 2,826 2,878 5,394 6,198 Performance Condition Awards 1,093 1,113 2,140 3,136 Market Condition Awards 1,372 3,042 2,767 6,189 Employee stock purchase plan — — 627 610 Share-based compensation expense 5,487 7,229 11,320 16,526 Less: income tax benefits (221) (385) (485) (1,026) Share-based compensation expense, net of income tax benefits $ 5,266 $ 6,844 $ 10,835 $ 15,500 Unrecognized Share-Based Compensation Expense As of August 31, 2024, our total unrecognized share-based compensation for all awards was $27.7 million, which will be recognized over a weighted average amortization period of 2.3 years. The total unrecognized share-based compensation reflects an estimate of target achievement for Performance Condition Awards granted during fiscal 2025 and fiscal 2024 and an estimate of zero percent of target achievement for Performance Condition Awards granted during fiscal 2023. |
Repurchases of Common Stock
Repurchases of Common Stock | 6 Months Ended |
Aug. 31, 2024 | |
Equity [Abstract] | |
Repurchases of Common Stock | Note 5 - Repurchases of Common Stock In August 2024, our Board of Directors authorized the repurchase of up to $500 million of our outstanding common stock. The authorization became effective August 20, 2024, for a period of three years, and replaced our former repurchase authorization, of which approximately $245.3 million remained. As of August 31, 2024, substantially all of our new repurchase authorization of $500.0 million remained available. Our current equity-based compensation plans include provisions that allow for the “net exercise” of share-settled awards by all plan participants. In a net exercise, any required payroll taxes, federal withholding taxes and exercise price of the shares due from the option or other share-based award holders are settled by having the holder tender back to us a number of shares at fair value equal to the amounts due. Net exercises are treated as purchases and retirements of shares. The following table summarizes our share repurchase activity for the periods shown: Three Months Ended August 31, Six Months Ended August 31, (in thousands, except share and per share data) 2024 2023 2024 2023 Common stock repurchased on the open market: Number of shares — 381,200 1,011,243 381,200 Aggregate value of shares $ — $ 50,006 $ 100,019 $ 50,006 Average price per share $ — $ 131.18 $ 98.91 $ 131.18 Common stock received in connection with share-based compensation: Number of shares 1,403 765 26,775 45,397 Aggregate value of shares $ 109 $ 83 $ 3,125 $ 4,529 Average price per share $ 78.07 $ 108.00 $ 116.72 $ 99.75 |
Restructuring Plan
Restructuring Plan | 6 Months Ended |
Aug. 31, 2024 | |
Restructuring and Related Activities [Abstract] | |
Restructuring Plan | Note 6 - Restructuring Plan During fiscal 2023, we initiated Project Pegasus, a global restructuring plan intended to expand operating margins through initiatives designed to improve efficiency and effectiveness and reduce costs. Project Pegasus includes initiatives to further optimize our brand portfolio, streamline and simplify the organization, accelerate and amplify cost of goods savings projects, enhance the efficiency of our supply chain network, optimize our indirect spending and improve our cash flow and working capital, as well as other activities. We anticipate these initiatives will create operating efficiencies, as well as provide a platform to fund future growth investments. During the fourth quarter of fiscal 2023, we made changes to the structure of our organization. These changes resulted in our previous Health & Wellness and Beauty operating segments being combined into a single reportable segment, the creation of a North America Regional Market Organization (“RMO”) responsible for sales and go-to-market strategies for all categories and channels in the U.S. and Canada, and further centralization of certain functions under shared services, particularly in operations and finance to better support our business segments and RMOs. This new structure reduced the size of our global workforce by approximately 10%. We believe that these changes better focus business segment resources on brand development, consumer-centric innovation and marketing, the RMOs on sales and go to market strategies, and shared services on their respective areas of expertise while also creating a more efficient and effective organizational structure. During the second quarter of fiscal 2024, we announced plans to geographically consolidate the U.S. Beauty business, currently located in El Paso, Texas, and Irvine, California, and co-locate it with our Wellness business in the Boston, Massachusetts area. This geographic consolidation and relocation is the next step in our initiative to streamline and simplify the organization and is expected to be completed during fiscal 2025. We expect these changes will enable a greater opportunity to capture synergies and enhance collaboration and innovation within the Beauty & Wellness segment. As previously disclosed, we continue to have the following expectations regarding Project Pegasus charges: • Total one-time pre-tax restructuring charges of approximately $50 million to $55 million over the duration of the plan, expected to be completed during fiscal 2025. • Pre-tax restructuring charges to be comprised of approximately $15 million to $19 million of severance and employee related costs, $28 million of professional fees, $3 million to $4 million of contract termination costs, and $4 million of other exit and disposal costs. • All of our operating segments and shared services will be impacted by the plan and pre-tax restructuring charges include approximately $16 million to $17 million in Home & Outdoor and $34 million to $38 million in Beauty & Wellness. • Pre-tax restructuring charges represent primarily cash expenditures, which are expected to be substantially paid by the end of fiscal 2025. We also continue to have the following expectations regarding Project Pegasus savings: • Targeted annualized pre-tax operating profit improvements of approximately $75 million to $85 million, which began in fiscal 2024 and we expect to be substantially achieved by the end of fiscal 2027. • Estimated cadence of the recognition of the savings will be approximately 25% in fiscal 2024, which was achieved, approximately 35% in fiscal 2025, approximately 25% in fiscal 2026 and approximately 15% in fiscal 2027. • Total profit improvements to be realized approximately 60% through reduced cost of goods sold and 40% through lower SG&A. During the three and six month periods ended August 31, 2024, we incurred $1.5 million and $3.4 million, respectively, of pre-tax restructuring costs in connection with Project Pegasus, which were recorded as “Restructuring charges” in the condensed consolidated statements of income. We recognized $3.6 million and $11.0 million of pre-tax restructuring costs during the three and six month periods ended August 31, 2023, respectively, in connection with Project Pegasus. The following tables summarize restructuring charges recorded as a result of Project Pegasus for the periods presented: Three Months Ended August 31, 2024 (in thousands) Home & Beauty & Total Severance and employee related costs $ 250 $ 541 $ 791 Professional fees 268 315 583 Contract termination — — — Other — 152 152 Total restructuring charges $ 518 $ 1,008 $ 1,526 Three Months Ended August 31, 2023 (in thousands) Home & Beauty & Total Severance and employee related costs $ 87 $ 501 $ 588 Professional fees 1,182 1,719 2,901 Contract termination — 108 108 Other 2 18 20 Total restructuring charges $ 1,271 $ 2,346 $ 3,617 Six Months Ended August 31, 2024 Total (in thousands) Home & Beauty & Wellness Total Severance and employee related costs $ 690 $ 1,666 $ 2,356 $ 17,632 Professional fees 268 585 853 27,730 Contract termination — — — 1,331 Other — 152 152 2,742 Total restructuring charges $ 958 $ 2,403 $ 3,361 $ 49,435 Six Months Ended August 31, 2023 (in thousands) Home & Beauty & Total Severance and employee related costs $ 571 $ 909 $ 1,480 Professional fees 3,451 5,076 8,527 Contract termination — 796 796 Other 39 130 169 Total restructuring charges $ 4,061 $ 6,911 $ 10,972 The tables below present a rollforward of our accruals related to Project Pegasus, which are included in accounts payable and accrued expenses and other current liabilities: (in thousands) Balance at February 29, 2024 Charges Payments Balance at August 31, 2024 Severance and employee related costs $ 4,493 $ 2,356 $ (4,852) $ 1,997 Professional fees 272 853 (599) 526 Contract termination — — — — Other — 152 (139) 13 Total $ 4,765 $ 3,361 $ (5,590) $ 2,536 (in thousands) Balance at February 28, 2023 Charges Payments Balance at August 31, 2023 Severance and employee related costs $ 3,173 $ 1,480 $ (3,422) $ 1,231 Professional fees 3,201 8,527 (10,635) 1,093 Contract termination 160 796 (956) — Other 34 169 (203) — Total $ 6,568 $ 10,972 $ (15,216) $ 2,324 |
Commitments and Contingencies
Commitments and Contingencies | 6 Months Ended |
Aug. 31, 2024 | |
Commitments and Contingencies Disclosure [Abstract] | |
Commitments and Contingencies | Note 7 - Commitments and Contingencies Legal Matters We are involved in various legal claims and proceedings in the normal course of operations. We believe the outcome of these matters will not have a material adverse effect on our consolidated financial position, results of operations or liquidity, except as described below. On December 23, 2021, Brita LP filed a complaint against Kaz USA, Inc. and Helen of Troy Limited in the United States District Court for the Western District of Texas (the “Patent Litigation”), alleging patent infringement by the Company relating to its PUR gravity-fed water filtration systems. In the Patent Litigation, Brita LP seeks monetary damages and injunctive relief relating to the alleged infringement. Brita LP simultaneously filed a complaint with the United States International Trade Commission (“ITC”) against Kaz USA, Inc., Helen of Troy Limited and five other unrelated companies that sell water filtration systems (the “ITC Action”). The complaint in the ITC Action also alleged patent infringement by the Company with respect to a limited set of PUR gravity-fed water filtration systems. In the ITC Action, Brita LP requested the ITC to initiate an unfair import investigation relating to such filtration systems. This action sought injunctive relief to prevent entry of certain accused PUR products (and certain other products) into the U.S. and cessation of marketing and sales of existing inventory that is already in the U.S. On January 25, 2022, the ITC instituted the investigation requested by the ITC Action. Discovery closed in the ITC Action in May 2022, and approximately half of the originally identified PUR gravity-fed water filters were removed from the case and are no longer included in the ITC Action. In August 2022, the parties participated in the evidentiary hearing, with additional supplemental hearings in October 2022. On February 28, 2023, the ITC issued an Initial Determination in the ITC Action, tentatively ruling against the Company and the other unrelated respondents. The ITC has a guaranteed review process, and thus all respondents, including the Company, filed a petition with the ITC for a full review of the Initial Determination. On September 19, 2023, the ITC issued its Final Determination in the Company’s favor. The ITC determined there was no violation by the Company and terminated the investigation. Brita LP is appealing the ITC's decision to the Federal Circuit (“CAFC Appeal”) and filed its Notice of Appeal on October 24, 2023. The Company intervened in the CAFC Appeal, but as of the filing date of this Form 10-Q, no hearings have been scheduled. The Patent Litigation remains stayed for the time being. We cannot predict the outcome of these legal proceedings, the amount or range of any potential loss, when the proceedings will be resolved, or customer acceptance of any replacement water filter. Litigation is inherently unpredictable, and the resolution or disposition of these proceedings could, if adversely determined, have a material and adverse impact on our financial position and results of operations. Regulatory Matters During fiscal 2022 and 2023, we were in discussions with the U.S. Environmental Protection Agency (the “EPA”) regarding the compliance of packaging claims on certain of our products in the air and water filtration categories and a limited subset of humidifier products within the Beauty & Wellness segment that are sold in the U.S. The EPA did not raise any product quality, safety or performance issues. As a result of these packaging compliance discussions, we voluntarily implemented a temporary stop shipment action on the impacted products as we worked with the EPA towards an expedient resolution. We resumed normalized levels of shipping of the affected inventory during fiscal 2022 and we completed the repackaging and relabeling of our existing inventory of impacted products during fiscal 2023. Additionally, as a result of continuing dialogue with the EPA, we executed further repackaging and relabeling plans on certain additional humidifier products and certain additional air filtration products, which were also completed during fiscal 2023. Ongoing settlement discussions with the EPA related to this matter may result in the imposition of fines or penalties in the future. Such potential fines or penalties cannot be estimated. For additional information refer to Part I, Item 2., “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” including “EPA Compliance Costs”. |
Long-Term Debt
Long-Term Debt | 6 Months Ended |
Aug. 31, 2024 | |
Debt Disclosure [Abstract] | |
Long-Term Debt | Note 8 - Long-Term Debt A summary of our long-term debt follows: (in thousands) August 31, 2024 February 29, 2024 Credit Agreement (1): Revolving loans $ 472,000 $ 421,950 Term loans 246,875 250,000 Total borrowings under Credit Agreement 718,875 671,950 Unamortized prepaid financing fees (5,640) (6,279) Total long-term debt 713,235 665,671 Less: current maturities of long-term debt (7,813) (6,250) Long-term debt, excluding current maturities $ 705,422 $ 659,421 (1) The weighted average interest rates on borrowings outstanding under the Credit Agreement (defined below) inclusive of the impact of our interest rate swaps as of August 31, 2024 and February 29, 2024 were 6.3% and 6.0%, respectively. Capitalized Interest During the three month periods ended August 31, 2024 and August 31, 2023, we incurred interest costs totaling $13.2 million and $13.7 million, respectively, of which none was capitalized. During the six month period ended August 31, 2024, we incurred interest costs totaling $25.8 million, of which none was capitalized, compared to $28.6 million for the same period last year, of which we capitalized $0.9 million as part of property and equipment in connection with the construction of a new distribution facility. Credit Agreement We have a credit agreement (the “Credit Agreement”) with Bank of America, N.A., as administrative agent, and other lenders that provides for aggregate commitments of $1.5 billion, which are available through (i) a $1.0 billion revolving credit facility, which includes a $50 million sublimit for the issuance of letters of credit, (ii) a $250 million term loan facility, and (iii) a committed $250 million delayed draw term loan facility, which may be borrowed in multiple drawdowns until August 15, 2025. Proceeds can be used for working capital and other general corporate purposes, including funding permitted acquisitions. At the closing date, February 15, 2024, we borrowed $457.5 million under the revolving credit facility and $250.0 million under the term loan facility and utilized the proceeds to repay all debt outstanding under our prior credit agreement. The Credit Agreement matures on February 15, 2029. The Credit Agreement includes an accordion feature, which permits the Company to request to increase its borrowing capacity by an additional $300 million plus an unlimited amount when the Leverage Ratio (as defined in the Credit Agreement) on a pro-forma basis is less than 3.25 to 1.00. The term loans are payable at the end of each fiscal quarter in equal installments of 0.625% through February 28, 2025, 0.9375% through February 28, 2026, and 1.25% thereafter of the original principal balance of the term loans, which began in the first quarter of fiscal 2025, with the remaining balance due at the maturity date. Borrowings under the Credit Agreement bear floating interest at either the Base Rate or Term SOFR (as defined in the Credit Agreement), plus a margin based on the Net Leverage Ratio (as defined in the Credit Agreement) of 0% to 1.125% and 1.0% to 2.125% for Base Rate and Term SOFR borrowings, respectively. The floating interest rates on our borrowings under the Credit Agreement are hedged with interest rate swaps to effectively fix interest rates on $300 million and $500 million of the outstanding principal balance under the revolving loans as of August 31, 2024 and February 29, 2024, respectively. See Notes 9, 10, and 11 for additional information regarding our interest rate swaps. As of August 31, 2024, the balance of outstanding letters of credit was $9.5 million and the amount available for revolving loans under the Credit Agreement was $518.5 million. Covenants in the Credit Agreement limit the amount of total indebtedness we can incur. As of August 31, 2024, these covenants effectively limited our ability to incur more than $322.8 million of additional debt from all sources, including the Credit Agreement, or $518.5 million in the event a qualified acquisition is consummated. Debt Covenants As of August 31, 2024, we were in compliance with all covenants as defined under the terms of the Credit Agreement. |
Fair Value
Fair Value | 6 Months Ended |
Aug. 31, 2024 | |
Fair Value Disclosures [Abstract] | |
Fair Value | Note 9 - Fair Value Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Valuation techniques under the accounting guidance related to fair value measurements are based on observable and unobservable inputs. These inputs are classified into the following hierarchy: Level 1: Quoted prices for identical assets or liabilities in active markets; Level 2: Observable inputs other than quoted prices that are directly or indirectly observable for the asset or liability, including quoted prices for similar assets or liabilities in active markets; quoted prices for similar or identical assets or liabilities in markets that are not active; and model-derived valuations whose inputs are observable or whose significant value drivers are observable; and Level 3: Unobservable inputs that reflect the reporting entity’s own assumptions. All of our financial assets and liabilities, except for our investments in U.S. Treasury Bills, are classified as Level 2 because their valuation is dependent on observable inputs and other quoted prices for similar assets or liabilities, or model-derived valuations whose significant value drivers are observable. Our investments in U.S. Treasury Bills are classified as Level 1 because their value is based on quoted prices in active markets for identical assets. The following table presents the fair value of our financial assets and liabilities: Fair Value (in thousands) August 31, 2024 February 29, 2024 Assets: Cash equivalents (money market accounts) $ 3,275 $ 462 U.S. Treasury Bills 9,267 8,948 Interest rate swaps — 2,504 Foreign currency derivatives 346 592 Total assets $ 12,888 $ 12,506 Liabilities: Interest rate swaps $ 788 $ — Foreign currency derivatives 1,501 386 Total liabilities $ 2,289 $ 386 All of our financial assets and liabilities, except for our investments in U.S. Treasury Bills, are measured and recorded at fair value on a recurring basis. Our investments in U.S. Treasury Bills are recorded at amortized cost. As of both August 31, 2024 and February 29, 2024, the current carrying amounts of our U.S. Treasury Bills were $2.5 million and were included within Prepaid expenses and other current assets in our condensed consolidated balance sheets. As of August 31, 2024 and February 29, 2024, the non-current carrying amounts of our U.S. Treasury Bills were $6.7 million and $6.6 million, respectively, and were included within Other assets in our condensed consolidated balance sheets. The carrying amounts of cash, accounts payable, accrued expenses and other current liabilities and income taxes payable approximate fair value because of the short maturity of these items. The carrying amounts of receivables approximate fair value due to the effect of the related allowance for credit losses. The carrying amount of our floating rate long-term debt approximates its fair value. Our investments in U.S. Treasury Bills are classified as held-to-maturity because we have the positive intent and ability to hold the securities to maturity. We invest in U.S. Treasury Bills with maturities ranging from less than one We use foreign currency forward contracts and interest rate swaps to manage our exposure to changes in foreign currency exchange rates and interest rates, respectively. All of our derivative assets and liabilities are recorded at fair value. See Notes 10 and 11 for more information on our derivatives. |
Financial Instruments and Risk
Financial Instruments and Risk Management | 6 Months Ended |
Aug. 31, 2024 | |
Derivative Instruments and Hedging Activities Disclosure [Abstract] | |
Financial Instruments and Risk Management | Note 10 - Financial Instruments and Risk Management Foreign Currency Risk The U.S. Dollar is the functional currency for the Company and all of its subsidiaries and is also the reporting currency for the Company. By operating internationally, we are subject to foreign currency risk from transactions denominated in currencies other than the U.S. Dollar (“foreign currencies”). Such transactions include sales and operating expenses. As a result of such transactions, portions of our cash, accounts receivable and accounts payable are denominated in foreign currencies. Approximately 12% of our net sales revenue was denominated in foreign currencies during both the three month periods ended August 31, 2024 and 2023, and 14% of our net sales revenue was denominated in foreign currencies during both the six month periods ended August 31, 2024 and 2023. These sales were primarily denominated in Euros, British Pounds and Canadian Dollars. We make most of our inventory purchases from manufacturers in Asia and primarily use the U.S. Dollar for such purchases. In our condensed consolidated statements of income, foreign currency exchange rate gains and losses resulting from the remeasurement of foreign income tax receivables and payables, and deferred income tax assets and liabilities are recognized in income tax expense, and all other foreign currency exchange rate gains and losses are recognized in SG&A. During the three and six month periods ended August 31, 2024, we recorded foreign currency exchange rate net losses of $0.2 million and $0.3 million, respectively, in income tax expense, compared to net gains of $0.2 million and $0.4 million for the same periods last year, respectively. During both the three and six month periods ended August 31, 2024, we recorded foreign currency exchange rate net gains of $0.6 million in SG&A, compared to net losses of $0.8 million and $0.4 million for the same periods last year, respectively. We mitigate certain foreign currency exchange rate risk by using forward contracts to protect against the foreign currency exchange rate risk inherent in our transactions denominated in foreign currencies. We do not enter into any derivatives or similar instruments for trading or other speculative purposes. Certain of our forward contracts are designated as cash flow hedges (“foreign currency contracts”) and are recorded on the balance sheet at fair value with changes in fair value recorded in Other Comprehensive Income (Loss) (“OCI”) until the hedge transaction is settled, at which point amounts are reclassified from Accumulated Other Comprehensive Income (Loss) (“AOCI”) to our condensed consolidated statements of income. Foreign currency derivatives for which we have not elected hedge accounting consist of certain forward contracts, and any changes in the fair value of these derivatives are recorded in our condensed consolidated statements of income. These undesignated derivatives are used to hedge monetary net asset and liability positions. Cash flows from our foreign currency derivatives are classified as cash flows from operating activities in our condensed consolidated statements of cash flows, which is consistent with the classification of the cash flows from the underlying hedged item. We evaluate our derivatives designated as cash flow hedges each quarter to assess hedge effectiveness. Interest Rate Risk Interest on our outstanding debt as of August 31, 2024 and February 29, 2024 is based on floating interest rates. If short-term interest rates increase, we will incur higher interest expense on any future outstanding balances of floating rate debt. Floating interest rates are hedged with interest rate swaps to effectively fix interest rates on a portion of our outstanding principal balance under the Credit Agreement, which totaled $718.9 million and $672.0 million as of August 31, 2024 and February 29, 2024, respectively. As of August 31, 2024 and February 29, 2024, $300.0 million and $500.0 million of the outstanding principal balance under the Credit Agreement, respectively, was hedged with interest rate swaps to fix the interest rate we pay. Our interest rate swaps are designated as cash flow hedges and are recorded on the balance sheet at fair value with changes in fair value recorded in OCI until the hedge transaction is settled, at which point amounts are reclassified from AOCI to our condensed consolidated statements of income. Cash flows from our interest rate swaps are classified as cash flows from operating activities in our condensed consolidated statements of cash flows, which is consistent with the classification of the cash flows from the underlying hedged item. We evaluate our derivatives designated as cash flow hedges each quarter to assess hedge effectiveness. The following tables summarize the fair values of our derivative instruments as of the end of the periods presented: (in thousands) August 31, 2024 Derivatives designated as hedging instruments Hedge Final Notional Amount Prepaid Other Assets Accrued Other Forward contracts - sell Euro Cash flow 2/2026 € 47,500 $ 134 $ 46 $ 277 $ 23 Forward contracts - sell Canadian Dollars Cash flow 2/2025 $ 14,250 82 — 68 — Forward contracts - sell Pounds Cash flow 2/2026 £ 30,800 9 3 956 177 Forward contracts - sell Norwegian Kroner Cash flow 8/2025 kr 16,500 22 — — — Interest rate swaps Cash flow 2/2026 $ 300,000 — — 528 260 Subtotal 247 49 1,829 460 Derivatives not designated under hedge accounting Forward contracts - buy Euro (1) 9/2024 € 2,450 23 — — — Forward contracts - buy Pounds (1) 9/2024 £ 790 27 — — — Subtotal 50 — — — Total fair value $ 297 $ 49 $ 1,829 $ 460 (in thousands) February 29, 2024 Derivatives designated as hedging instruments Hedge Type Final Notional Amount Prepaid Other Assets Accrued Other Forward contracts - sell Euro Cash flow 2/2025 € 36,500 $ 377 $ — $ 90 $ — Forward contracts - sell Canadian Dollars Cash flow 2/2025 $ 20,750 151 — 57 — Forward contracts - sell Pounds Cash flow 2/2025 £ 20,250 59 — 234 — Forward contracts - sell Norwegian Kroner Cash flow 8/2024 kr 5,000 5 — — — Interest rate swaps Cash flow 2/2026 $ 500,000 1,314 1,190 — — Subtotal 1,906 1,190 381 — Derivatives not designated under hedge accounting Forward contracts - sell Euro (1) 3/2024 € 430 — — 3 — Forward contracts - sell Pounds (1) 3/2024 £ 735 — — 2 — Subtotal — — 5 — Total fair value $ 1,906 $ 1,190 $ 386 $ — (1) These forward contracts, for which we have not elected hedge accounting, hedge monetary net asset and liability positions for the notional amounts reported, creating an economic hedge against currency movements. The pre-tax effects of derivative instruments designated as cash flow hedges were as follows for the periods presented: Three Months Ended August 31, Gain (Loss) Gain (Loss) Reclassified (in thousands) 2024 2023 Location 2024 2023 Foreign currency contracts - cash flow hedges $ (1,317) $ (779) Sales revenue, net $ (193) $ (383) Interest rate swaps - cash flow hedges (3,535) 5,644 Interest expense 965 2,027 Total $ (4,852) $ 4,865 $ 772 $ 1,644 Six Months Ended August 31, Gain (Loss) Gain (Loss) Reclassified (in thousands) 2024 2023 Location 2024 2023 Foreign currency contracts - cash flow hedges $ (1,425) $ (1,246) Sales revenue, net $ (9) $ (45) Interest rate swaps - cash flow hedges (1,243) 3,010 Interest expense 2,049 3,434 Total $ (2,668) $ 1,764 $ 2,040 $ 3,389 The pre-tax effects of derivative instruments not designated under hedge accounting were as follows for the periods presented: Gain (Loss) Three Months Ended August 31, Six Months Ended August 31, (in thousands) Location 2024 2023 2024 2023 Forward contracts SG&A $ 66 $ (16) $ 88 $ (40) Total $ 66 $ (16) $ 88 $ (40) We expect a net loss of $1.6 million associated with foreign currency contracts and interest rate swaps currently recorded in AOCI to be reclassified into income over the next twelve months. The amount ultimately realized, however, will differ as exchange rates and interest rates change and the underlying contracts settle. See Notes 9 and 11 for more information. Counterparty Credit Risk Financial instruments, including foreign currency contracts, forward contracts, and interest rate swaps, expose us to counterparty credit risk for non-performance. We manage our exposure to counterparty credit risk by only dealing with counterparties who are substantial international financial institutions with significant experience using such derivative instruments. We believe that the risk of incurring credit losses is remote. |
Accumulated Other Comprehensive
Accumulated Other Comprehensive Income (Loss) | 6 Months Ended |
Aug. 31, 2024 | |
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract] | |
Accumulated Other Comprehensive Income (Loss) | Note 11 - Accumulated Other Comprehensive Income (Loss) The changes in AOCI by component and related tax effects for the periods presented were as follows: (in thousands) Interest Foreign Total Balance at February 28, 2023 $ 4,394 $ 553 $ 4,947 Other comprehensive income (loss) before reclassification 3,010 (1,246) 1,764 Amounts reclassified out of AOCI (3,434) 45 (3,389) Tax effects 100 264 364 Other comprehensive loss (324) (937) (1,261) Balance at August 31, 2023 $ 4,070 $ (384) $ 3,686 Balance at February 29, 2024 $ 1,917 $ 182 $ 2,099 Other comprehensive loss before reclassification (1,243) (1,425) (2,668) Amounts reclassified out of AOCI (2,049) 9 (2,040) Tax effects 771 323 1,094 Other comprehensive loss (2,521) (1,093) (3,614) Balance at August 31, 2024 $ (604) $ (911) $ (1,515) See Notes 9 and 10 for additional information regarding our cash flow hedges. |
Segment and Geographic Informat
Segment and Geographic Information | 6 Months Ended |
Aug. 31, 2024 | |
Segment Reporting [Abstract] | |
Segment and Geographic Information | Note 12 - Segment and Geographic Information The following tables summarize segment information for the periods presented: Three Months Ended August 31, 2024 (in thousands) Home & Outdoor Beauty & Wellness Total Sales revenue, net $ 241,944 $ 232,277 $ 474,221 Restructuring charges 518 1,008 1,526 Operating income 31,152 3,700 34,852 Capital and intangible asset expenditures 1,722 3,162 4,884 Depreciation and amortization 6,590 7,202 13,792 Three Months Ended August 31, 2023 (in thousands) Home & Outdoor Beauty & Wellness Total Sales revenue, net $ 239,977 $ 251,586 $ 491,563 Restructuring charges 1,271 2,346 3,617 Operating income 36,099 10,746 46,845 Capital and intangible asset expenditures 4,879 3,801 8,680 Depreciation and amortization 6,606 7,285 13,891 Six Months Ended August 31, 2024 (in thousands) Home & Outdoor Beauty & Wellness Total Sales revenue, net $ 440,403 $ 450,665 $ 891,068 Restructuring charges 958 2,403 3,361 Operating income 47,002 18,613 65,615 Capital and intangible asset expenditures 7,467 6,559 14,026 Depreciation and amortization 13,237 14,391 27,628 Six Months Ended August 31, 2023 (in thousands) Home & Outdoor Beauty & Wellness Total Sales revenue, net $ 457,121 $ 509,114 $ 966,235 Restructuring charges 4,061 6,911 10,972 Operating income 58,215 29,271 87,486 Capital and intangible asset expenditures 15,839 4,718 20,557 Depreciation and amortization 11,008 13,598 24,606 The following table presents net sales revenue by geographic region, in U.S. Dollars: Three Months Ended August 31, Six Months Ended August 31, (in thousands) 2024 2023 2024 2023 Domestic sales revenue, net (1) $ 365,750 77.1 % $ 388,049 78.9 % $ 666,430 74.8 % $ 747,608 77.4 % International sales revenue, net 108,471 22.9 % 103,514 21.1 % 224,638 25.2 % 218,627 22.6 % Total sales revenue, net $ 474,221 100.0 % $ 491,563 100.0 % $ 891,068 100.0 % $ 966,235 100.0 % (1) |
Income Taxes
Income Taxes | 6 Months Ended |
Aug. 31, 2024 | |
Income Tax Disclosure [Abstract] | |
Income Taxes | Note 13 - Income Taxes We reorganized the Company in Bermuda in 1994 and many of our foreign subsidiaries are not directly or indirectly owned by a U.S. parent. As such, a large portion of our foreign income is not subject to U.S. taxation on a permanent basis under current law. Additionally, our intellectual property is largely owned by foreign subsidiaries, resulting in proportionally higher earnings in jurisdictions with lower statutory tax rates, which decreases our overall effective tax rate. The taxable income earned in each jurisdiction, whether U.S. or foreign, is determined by the subsidiary's operating results and transfer pricing and tax regulations in the related jurisdictions. For interim periods, our income tax expense and resulting effective tax rate are based upon an estimated annual effective tax rate adjusted for the effects of items required to be treated as discrete to the period, including changes in tax laws, changes in estimated exposures for uncertain tax positions and other items. The Organisation for Economic Co-operation and Development has introduced a framework to implement a global minimum corporate income tax of 15%, referred to as “Pillar Two.” Many aspects of Pillar Two are effective for tax years beginning after January 1, 2024, with certain remaining aspects to be effective for tax years beginning January 1, 2025 or later. Certain countries have adopted legislation to implement Pillar Two, and other countries are in the process of introducing legislation to implement Pillar Two. We will continue to assess the impact of Pillar Two and monitor developments in legislation, regulation, and interpretive guidance. In response to Pillar Two, on May 24, 2024, Barbados enacted a domestic corporate income tax rate of 9%, effective beginning with our fiscal year 2025. As a result, we incorporated this corporate income tax into our estimated annual effective tax rate increasing our income tax provision beginning in the first quarter of fiscal 2025. In addition, we revalued our existing deferred tax liabilities subject to the Barbados legislation, which resulted in a discrete tax charge of $6.0 million during the first quarter of fiscal 2025. Additionally, Barbados enacted a domestic minimum top-up tax (“DMTT”) of 15% which applies to Barbados businesses that are part of multinational enterprise groups with annual revenue of €750 million or more and is effective beginning with our fiscal year 2026. We will continue to monitor and evaluate impacts as further regulatory guidance becomes available. For the three months ended August 31, 2024, income tax expense as a percentage of income before income tax was 22.0% compared to 17.9% for the same period last year. The year-over-year increase in the effective tax rate is primarily due to the Barbados tax legislation enacted during the first quarter of fiscal 2025, which resulted in an increase in our income tax expense due to the change to our estimated annual effective tax rate arising from the legislation, shifts in the mix of income in our various tax jurisdictions, and an increase in tax expense for discrete items. For the six months ended August 31, 2024, income tax expense as a percentage of income before income tax was 42.1% compared to 16.8% for the same period last year primarily due to the Barbados tax legislation described above, including a discrete tax charge of $6.0 million during the first quarter of fiscal 2025 to revalue deferred tax liabilities. |
Earnings Per Share
Earnings Per Share | 6 Months Ended |
Aug. 31, 2024 | |
Earnings Per Share [Abstract] | |
Earnings Per Share | Note 14 - Earnings Per Share We compute basic earnings per share using the weighted average number of shares of common stock outstanding during the period. We compute diluted earnings per share using the weighted average number of shares of common stock outstanding plus the effect of dilutive securities. Dilutive securities at any given point in time may consist of outstanding options to purchase common stock and issued and contingently issuable unvested restricted stock units, performance stock units, restricted stock awards and performance restricted stock awards and other stock-based awards. Anti-dilutive securities are not included in the computation of diluted earnings per share under the treasury stock method. See Note 4 to these condensed consolidated financial statements for more information regarding stock-based awards. The following table presents our weighted average basic and diluted shares outstanding for the periods shown: Three Months Ended August 31, Six Months Ended August 31, (in thousands) 2024 2023 2024 2023 Weighted average shares outstanding, basic 22,814 23,918 23,169 23,984 Incremental shares from share-based compensation arrangements 25 123 67 104 Weighted average shares outstanding, diluted 22,839 24,041 23,236 24,088 Anti-dilutive securities 155 7 140 81 |
Pay vs Performance Disclosure
Pay vs Performance Disclosure - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | ||
Aug. 31, 2024 | Aug. 31, 2023 | Aug. 31, 2024 | Aug. 31, 2023 | |
Pay vs Performance Disclosure | ||||
Net income | $ 17,014 | $ 27,381 | $ 23,218 | $ 49,962 |
Insider Trading Arrangements
Insider Trading Arrangements | 3 Months Ended |
Aug. 31, 2024 | |
Trading Arrangements, by Individual | |
Rule 10b5-1 Arrangement Adopted | false |
Non-Rule 10b5-1 Arrangement Adopted | false |
Rule 10b5-1 Arrangement Terminated | false |
Non-Rule 10b5-1 Arrangement Terminated | false |
Basis of Presentation and Rel_2
Basis of Presentation and Related Information (Policies) | 6 Months Ended |
Aug. 31, 2024 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Principles of Consolidation | Principles of Consolidation The accompanying condensed consolidated financial statements are prepared in accordance with GAAP and include all of our subsidiaries. Our condensed consolidated financial statements are prepared in U.S. Dollars. All intercompany balances and transactions are eliminated in consolidation. The preparation of consolidated financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the amounts reported in our condensed consolidated financial statements and accompanying notes. Actual results may differ materially from those estimates. During the second quarter of fiscal 2025, we concluded that a goodwill impairment triggering event had occurred primarily due to a sustained decline in our stock price. Additional factors that contributed to this conclusion included current macroeconomic trends and uncertainty surrounding inflation and high interest rates, which negatively impact consumer disposable income, credit availability, spending and overall consumer confidence, all of which have and may continue to adversely impact our sales, results of operations and cash flows. These factors are applicable to all of our reporting units which resulted in us performing quantitative goodwill impairment testing on all of our reporting units. We considered whether these events and circumstances would affect any other assets and concluded to perform quantitative impairment testing on our indefinite-lived trademark licenses and trade names and our definite-lived trademark licenses, trade names, and customer lists. We performed quantitative impairment testing on our goodwill and intangible assets described above and determined none were impaired. Accordingly, no impairment charges were recorded. For additional information, refer to “Critical Accounting Policies and Estimates” in Item 2., “Management's Discussion and Analysis of Financial Condition and Results of Operations”. |
Accrued Expenses and Other Cu_2
Accrued Expenses and Other Current Liabilities (Tables) | 6 Months Ended |
Aug. 31, 2024 | |
Payables and Accruals [Abstract] | |
Schedule of accrued expenses and other current liabilities | A summary of accrued expenses and other current liabilities was as follows: (in thousands) August 31, 2024 February 29, 2024 Accrued compensation, benefits and payroll taxes $ 19,740 $ 36,572 Accrued sales discounts and allowances 39,984 37,851 Accrued sales returns 20,910 21,282 Accrued advertising 27,503 29,212 Other 55,547 56,474 Total accrued expenses and other current liabilities $ 163,684 $ 181,391 |
Share-Based Compensation Plans
Share-Based Compensation Plans (Tables) | 6 Months Ended |
Aug. 31, 2024 | |
Share-Based Payment Arrangement [Abstract] | |
Share-based compensation expense in SG&A | We recorded share-based compensation expense in SG&A as follows: Three Months Ended August 31, Six Months Ended (in thousands) 2024 2023 2024 2023 Directors stock compensation $ 196 $ 196 $ 392 $ 393 Service Condition Awards 2,826 2,878 5,394 6,198 Performance Condition Awards 1,093 1,113 2,140 3,136 Market Condition Awards 1,372 3,042 2,767 6,189 Employee stock purchase plan — — 627 610 Share-based compensation expense 5,487 7,229 11,320 16,526 Less: income tax benefits (221) (385) (485) (1,026) Share-based compensation expense, net of income tax benefits $ 5,266 $ 6,844 $ 10,835 $ 15,500 |
Repurchases of Common Stock (Ta
Repurchases of Common Stock (Tables) | 6 Months Ended |
Aug. 31, 2024 | |
Equity [Abstract] | |
Summary of share repurchase activity | The following table summarizes our share repurchase activity for the periods shown: Three Months Ended August 31, Six Months Ended August 31, (in thousands, except share and per share data) 2024 2023 2024 2023 Common stock repurchased on the open market: Number of shares — 381,200 1,011,243 381,200 Aggregate value of shares $ — $ 50,006 $ 100,019 $ 50,006 Average price per share $ — $ 131.18 $ 98.91 $ 131.18 Common stock received in connection with share-based compensation: Number of shares 1,403 765 26,775 45,397 Aggregate value of shares $ 109 $ 83 $ 3,125 $ 4,529 Average price per share $ 78.07 $ 108.00 $ 116.72 $ 99.75 |
Restructuring Plan (Tables)
Restructuring Plan (Tables) | 6 Months Ended |
Aug. 31, 2024 | |
Restructuring and Related Activities [Abstract] | |
Summary of restructuring charges recorded | The following tables summarize restructuring charges recorded as a result of Project Pegasus for the periods presented: Three Months Ended August 31, 2024 (in thousands) Home & Beauty & Total Severance and employee related costs $ 250 $ 541 $ 791 Professional fees 268 315 583 Contract termination — — — Other — 152 152 Total restructuring charges $ 518 $ 1,008 $ 1,526 Three Months Ended August 31, 2023 (in thousands) Home & Beauty & Total Severance and employee related costs $ 87 $ 501 $ 588 Professional fees 1,182 1,719 2,901 Contract termination — 108 108 Other 2 18 20 Total restructuring charges $ 1,271 $ 2,346 $ 3,617 Six Months Ended August 31, 2024 Total (in thousands) Home & Beauty & Wellness Total Severance and employee related costs $ 690 $ 1,666 $ 2,356 $ 17,632 Professional fees 268 585 853 27,730 Contract termination — — — 1,331 Other — 152 152 2,742 Total restructuring charges $ 958 $ 2,403 $ 3,361 $ 49,435 Six Months Ended August 31, 2023 (in thousands) Home & Beauty & Total Severance and employee related costs $ 571 $ 909 $ 1,480 Professional fees 3,451 5,076 8,527 Contract termination — 796 796 Other 39 130 169 Total restructuring charges $ 4,061 $ 6,911 $ 10,972 |
Rollforward of restructuring reserve | The tables below present a rollforward of our accruals related to Project Pegasus, which are included in accounts payable and accrued expenses and other current liabilities: (in thousands) Balance at February 29, 2024 Charges Payments Balance at August 31, 2024 Severance and employee related costs $ 4,493 $ 2,356 $ (4,852) $ 1,997 Professional fees 272 853 (599) 526 Contract termination — — — — Other — 152 (139) 13 Total $ 4,765 $ 3,361 $ (5,590) $ 2,536 (in thousands) Balance at February 28, 2023 Charges Payments Balance at August 31, 2023 Severance and employee related costs $ 3,173 $ 1,480 $ (3,422) $ 1,231 Professional fees 3,201 8,527 (10,635) 1,093 Contract termination 160 796 (956) — Other 34 169 (203) — Total $ 6,568 $ 10,972 $ (15,216) $ 2,324 |
Long-Term Debt (Tables)
Long-Term Debt (Tables) | 6 Months Ended |
Aug. 31, 2024 | |
Debt Disclosure [Abstract] | |
Summary of long-term debt | A summary of our long-term debt follows: (in thousands) August 31, 2024 February 29, 2024 Credit Agreement (1): Revolving loans $ 472,000 $ 421,950 Term loans 246,875 250,000 Total borrowings under Credit Agreement 718,875 671,950 Unamortized prepaid financing fees (5,640) (6,279) Total long-term debt 713,235 665,671 Less: current maturities of long-term debt (7,813) (6,250) Long-term debt, excluding current maturities $ 705,422 $ 659,421 (1) The weighted average interest rates on borrowings outstanding under the Credit Agreement (defined below) inclusive of the impact of our interest rate swaps as of August 31, 2024 and February 29, 2024 were 6.3% and 6.0%, respectively. |
Fair Value (Tables)
Fair Value (Tables) | 6 Months Ended |
Aug. 31, 2024 | |
Fair Value Disclosures [Abstract] | |
Schedule of carrying value and fair value of financial assets and liabilities recorded at fair value and measured on a recurring basis and classified as level 2 | The following table presents the fair value of our financial assets and liabilities: Fair Value (in thousands) August 31, 2024 February 29, 2024 Assets: Cash equivalents (money market accounts) $ 3,275 $ 462 U.S. Treasury Bills 9,267 8,948 Interest rate swaps — 2,504 Foreign currency derivatives 346 592 Total assets $ 12,888 $ 12,506 Liabilities: Interest rate swaps $ 788 $ — Foreign currency derivatives 1,501 386 Total liabilities $ 2,289 $ 386 |
Financial Instruments and Ris_2
Financial Instruments and Risk Management (Tables) | 6 Months Ended |
Aug. 31, 2024 | |
Derivative Instruments and Hedging Activities Disclosure [Abstract] | |
Schedule of fair values of derivative instruments | The following tables summarize the fair values of our derivative instruments as of the end of the periods presented: (in thousands) August 31, 2024 Derivatives designated as hedging instruments Hedge Final Notional Amount Prepaid Other Assets Accrued Other Forward contracts - sell Euro Cash flow 2/2026 € 47,500 $ 134 $ 46 $ 277 $ 23 Forward contracts - sell Canadian Dollars Cash flow 2/2025 $ 14,250 82 — 68 — Forward contracts - sell Pounds Cash flow 2/2026 £ 30,800 9 3 956 177 Forward contracts - sell Norwegian Kroner Cash flow 8/2025 kr 16,500 22 — — — Interest rate swaps Cash flow 2/2026 $ 300,000 — — 528 260 Subtotal 247 49 1,829 460 Derivatives not designated under hedge accounting Forward contracts - buy Euro (1) 9/2024 € 2,450 23 — — — Forward contracts - buy Pounds (1) 9/2024 £ 790 27 — — — Subtotal 50 — — — Total fair value $ 297 $ 49 $ 1,829 $ 460 (in thousands) February 29, 2024 Derivatives designated as hedging instruments Hedge Type Final Notional Amount Prepaid Other Assets Accrued Other Forward contracts - sell Euro Cash flow 2/2025 € 36,500 $ 377 $ — $ 90 $ — Forward contracts - sell Canadian Dollars Cash flow 2/2025 $ 20,750 151 — 57 — Forward contracts - sell Pounds Cash flow 2/2025 £ 20,250 59 — 234 — Forward contracts - sell Norwegian Kroner Cash flow 8/2024 kr 5,000 5 — — — Interest rate swaps Cash flow 2/2026 $ 500,000 1,314 1,190 — — Subtotal 1,906 1,190 381 — Derivatives not designated under hedge accounting Forward contracts - sell Euro (1) 3/2024 € 430 — — 3 — Forward contracts - sell Pounds (1) 3/2024 £ 735 — — 2 — Subtotal — — 5 — Total fair value $ 1,906 $ 1,190 $ 386 $ — (1) |
Schedule of pre-tax effect of derivative instruments designated as hedges | The pre-tax effects of derivative instruments designated as cash flow hedges were as follows for the periods presented: Three Months Ended August 31, Gain (Loss) Gain (Loss) Reclassified (in thousands) 2024 2023 Location 2024 2023 Foreign currency contracts - cash flow hedges $ (1,317) $ (779) Sales revenue, net $ (193) $ (383) Interest rate swaps - cash flow hedges (3,535) 5,644 Interest expense 965 2,027 Total $ (4,852) $ 4,865 $ 772 $ 1,644 Six Months Ended August 31, Gain (Loss) Gain (Loss) Reclassified (in thousands) 2024 2023 Location 2024 2023 Foreign currency contracts - cash flow hedges $ (1,425) $ (1,246) Sales revenue, net $ (9) $ (45) Interest rate swaps - cash flow hedges (1,243) 3,010 Interest expense 2,049 3,434 Total $ (2,668) $ 1,764 $ 2,040 $ 3,389 |
Schedule of pre-tax effect of derivative instruments not designated as hedges | The pre-tax effects of derivative instruments not designated under hedge accounting were as follows for the periods presented: Gain (Loss) Three Months Ended August 31, Six Months Ended August 31, (in thousands) Location 2024 2023 2024 2023 Forward contracts SG&A $ 66 $ (16) $ 88 $ (40) Total $ 66 $ (16) $ 88 $ (40) |
Accumulated Other Comprehensi_2
Accumulated Other Comprehensive Income (Loss) (Tables) | 6 Months Ended |
Aug. 31, 2024 | |
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract] | |
Summary of changes in accumulated other comprehensive income (loss) | The changes in AOCI by component and related tax effects for the periods presented were as follows: (in thousands) Interest Foreign Total Balance at February 28, 2023 $ 4,394 $ 553 $ 4,947 Other comprehensive income (loss) before reclassification 3,010 (1,246) 1,764 Amounts reclassified out of AOCI (3,434) 45 (3,389) Tax effects 100 264 364 Other comprehensive loss (324) (937) (1,261) Balance at August 31, 2023 $ 4,070 $ (384) $ 3,686 Balance at February 29, 2024 $ 1,917 $ 182 $ 2,099 Other comprehensive loss before reclassification (1,243) (1,425) (2,668) Amounts reclassified out of AOCI (2,049) 9 (2,040) Tax effects 771 323 1,094 Other comprehensive loss (2,521) (1,093) (3,614) Balance at August 31, 2024 $ (604) $ (911) $ (1,515) |
Segment and Geographic Inform_2
Segment and Geographic Information (Tables) | 6 Months Ended |
Aug. 31, 2024 | |
Segment Reporting [Abstract] | |
Schedule of segment information | The following tables summarize segment information for the periods presented: Three Months Ended August 31, 2024 (in thousands) Home & Outdoor Beauty & Wellness Total Sales revenue, net $ 241,944 $ 232,277 $ 474,221 Restructuring charges 518 1,008 1,526 Operating income 31,152 3,700 34,852 Capital and intangible asset expenditures 1,722 3,162 4,884 Depreciation and amortization 6,590 7,202 13,792 Three Months Ended August 31, 2023 (in thousands) Home & Outdoor Beauty & Wellness Total Sales revenue, net $ 239,977 $ 251,586 $ 491,563 Restructuring charges 1,271 2,346 3,617 Operating income 36,099 10,746 46,845 Capital and intangible asset expenditures 4,879 3,801 8,680 Depreciation and amortization 6,606 7,285 13,891 Six Months Ended August 31, 2024 (in thousands) Home & Outdoor Beauty & Wellness Total Sales revenue, net $ 440,403 $ 450,665 $ 891,068 Restructuring charges 958 2,403 3,361 Operating income 47,002 18,613 65,615 Capital and intangible asset expenditures 7,467 6,559 14,026 Depreciation and amortization 13,237 14,391 27,628 Six Months Ended August 31, 2023 (in thousands) Home & Outdoor Beauty & Wellness Total Sales revenue, net $ 457,121 $ 509,114 $ 966,235 Restructuring charges 4,061 6,911 10,972 Operating income 58,215 29,271 87,486 Capital and intangible asset expenditures 15,839 4,718 20,557 Depreciation and amortization 11,008 13,598 24,606 The following table presents net sales revenue by geographic region, in U.S. Dollars: Three Months Ended August 31, Six Months Ended August 31, (in thousands) 2024 2023 2024 2023 Domestic sales revenue, net (1) $ 365,750 77.1 % $ 388,049 78.9 % $ 666,430 74.8 % $ 747,608 77.4 % International sales revenue, net 108,471 22.9 % 103,514 21.1 % 224,638 25.2 % 218,627 22.6 % Total sales revenue, net $ 474,221 100.0 % $ 491,563 100.0 % $ 891,068 100.0 % $ 966,235 100.0 % (1) |
Earnings Per Share (Tables)
Earnings Per Share (Tables) | 6 Months Ended |
Aug. 31, 2024 | |
Earnings Per Share [Abstract] | |
Schedule of components of basic and diluted shares | The following table presents our weighted average basic and diluted shares outstanding for the periods shown: Three Months Ended August 31, Six Months Ended August 31, (in thousands) 2024 2023 2024 2023 Weighted average shares outstanding, basic 22,814 23,918 23,169 23,984 Incremental shares from share-based compensation arrangements 25 123 67 104 Weighted average shares outstanding, diluted 22,839 24,041 23,236 24,088 Anti-dilutive securities 155 7 140 81 |
Basis of Presentation and Rel_3
Basis of Presentation and Related Information (Details) | 3 Months Ended | |
Aug. 31, 2024 USD ($) segment $ / shares | Feb. 29, 2024 $ / shares | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | ||
Common shares, par value (in dollars per share) | $ / shares | $ 0.10 | $ 0.10 |
Number of segments | segment | 2 | |
Goodwill and intangible asset impairment | $ | $ 0 |
Accrued Expenses and Other Cu_3
Accrued Expenses and Other Current Liabilities (Details) - USD ($) $ in Thousands | Aug. 31, 2024 | Feb. 29, 2024 |
Payables and Accruals [Abstract] | ||
Accrued compensation, benefits and payroll taxes | $ 19,740 | $ 36,572 |
Accrued sales discounts and allowances | 39,984 | 37,851 |
Accrued sales returns | 20,910 | 21,282 |
Accrued advertising | 27,503 | 29,212 |
Other | 55,547 | 56,474 |
Accrued expenses and other current liabilities | $ 163,684 | $ 181,391 |
Share-Based Compensation Plan_2
Share-Based Compensation Plans - Narrative (Details) $ / shares in Units, $ in Millions | 3 Months Ended | 6 Months Ended |
Aug. 31, 2024 USD ($) $ / shares shares | Aug. 31, 2024 USD ($) | |
Share-based compensation plans | ||
Expected recognition period for unrecognized share-based compensation | 2 years 3 months 18 days | |
Target achievement for performance condition awards, as a percentage | 0% | 0% |
Restricted Stock | ||
Share-based compensation plans | ||
Number of awards granted (in shares) | 157,797 | |
Unrecognized share-based compensation | $ | $ 27.7 | $ 27.7 |
Service Condition Awards | ||
Share-based compensation plans | ||
Number of awards granted (in shares) | 94,900 | |
Grant date fair value of shares granted in period (in dollars per share) | $ / shares | $ 124.37 | |
Market Condition Awards | ||
Share-based compensation plans | ||
Number of awards granted (in shares) | 63,211 | |
Grant date fair value of shares granted in period (in dollars per share) | $ / shares | $ 91.19 | |
Performance Condition Awards | ||
Share-based compensation plans | ||
Number of awards granted (in shares) | 94,586 | |
Grant date fair value of shares granted in period (in dollars per share) | $ / shares | $ 124.37 |
Share-Based Compensation Plan_3
Share-Based Compensation Plans - Share-Based Compensation Expense in SG&A (Details) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | ||
Aug. 31, 2024 | Aug. 31, 2023 | Aug. 31, 2024 | Aug. 31, 2023 | |
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] | ||||
Share-based compensation expense, net of income tax benefits | $ 5,266 | $ 6,844 | $ 10,835 | $ 15,500 |
SG&A | ||||
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] | ||||
Share-based compensation expense | 5,487 | 7,229 | 11,320 | 16,526 |
Less: income tax benefits | (221) | (385) | (485) | (1,026) |
Service Condition Awards | SG&A | ||||
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] | ||||
Share-based compensation expense | 2,826 | 2,878 | 5,394 | 6,198 |
Performance Condition Awards | SG&A | ||||
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] | ||||
Share-based compensation expense | 1,093 | 1,113 | 2,140 | 3,136 |
Market Condition Awards | SG&A | ||||
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] | ||||
Share-based compensation expense | 1,372 | 3,042 | 2,767 | 6,189 |
Employee stock purchase plan | SG&A | ||||
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] | ||||
Share-based compensation expense | 0 | 0 | 627 | 610 |
Directors stock compensation | SG&A | ||||
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] | ||||
Share-based compensation expense | $ 196 | $ 196 | $ 392 | $ 393 |
Repurchases of Common Stock - N
Repurchases of Common Stock - Narrative (Details) - USD ($) | Aug. 20, 2024 | Aug. 31, 2024 | Aug. 19, 2024 |
Equity [Abstract] | |||
Amount of shares authorized for purchase | $ 500,000,000 | ||
Period for stock repurchase | 3 years | ||
Remaining share repurchase amount | $ 500,000,000 | $ 245,300,000 |
Repurchases of Common Stock - S
Repurchases of Common Stock - Summary of Share Repurchase Activity (Details) - USD ($) $ / shares in Units, $ in Thousands | 3 Months Ended | 6 Months Ended | ||||
Aug. 31, 2024 | May 31, 2024 | Aug. 31, 2023 | May 31, 2023 | Aug. 31, 2024 | Aug. 31, 2023 | |
Repurchase of common stock | ||||||
Aggregate value of shares | $ 109 | $ 103,035 | $ 50,089 | $ 4,446 | ||
Stock Compensation Plan | ||||||
Repurchase of common stock | ||||||
Number of shares (in shares) | 1,403 | 765 | 26,775 | 45,397 | ||
Aggregate value of shares | $ 109 | $ 83 | $ 3,125 | $ 4,529 | ||
Average price per share (in dollars per share) | $ 78.07 | $ 108 | $ 116.72 | $ 99.75 | ||
Open Market | ||||||
Repurchase of common stock | ||||||
Number of shares (in shares) | 0 | 381,200 | 1,011,243 | 381,200 | ||
Aggregate value of shares | $ 0 | $ 50,006 | $ 100,019 | $ 50,006 | ||
Average price per share (in dollars per share) | $ 0 | $ 131.18 | $ 98.91 | $ 131.18 |
Restructuring Plan - Narrative
Restructuring Plan - Narrative (Details) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | 24 Months Ended | |||
Aug. 31, 2024 | Aug. 31, 2023 | Aug. 31, 2024 | Aug. 31, 2023 | May 31, 2024 | Feb. 29, 2024 | |
Restructuring Plan | ||||||
Restructuring charges | $ 1,526 | $ 3,617 | $ 3,361 | $ 10,972 | ||
Project Pegasus | ||||||
Restructuring Plan | ||||||
Estimated percentage of workforce reduction | 10% | |||||
Estimated percentage reduction in cost of goods sold | 60% | |||||
Estimated percentage reduction in SG&A expenses | 40% | |||||
Restructuring charges | $ 1,526 | 3,617 | 3,361 | 10,972 | $ 49,435 | |
Project Pegasus | Home & Outdoor | ||||||
Restructuring Plan | ||||||
Restructuring charges | 518 | 1,271 | 958 | 4,061 | ||
Project Pegasus | Beauty & Wellness | ||||||
Restructuring Plan | ||||||
Restructuring charges | 1,008 | 2,346 | 2,403 | 6,911 | ||
Project Pegasus | Severance and employee related costs | ||||||
Restructuring Plan | ||||||
Restructuring charges | 2,356 | 1,480 | ||||
Project Pegasus | Professional fees | ||||||
Restructuring Plan | ||||||
Expected restructuring costs | 28,000 | 28,000 | ||||
Restructuring charges | 853 | 8,527 | ||||
Project Pegasus | Contract termination | ||||||
Restructuring Plan | ||||||
Restructuring charges | 0 | 796 | ||||
Project Pegasus | Other | ||||||
Restructuring Plan | ||||||
Restructuring charges | $ 152 | 169 | ||||
Project Pegasus | Fiscal 2024 | ||||||
Restructuring Plan | ||||||
Estimated percentage of savings recognized | 25% | |||||
Project Pegasus | Fiscal 2025 | ||||||
Restructuring Plan | ||||||
Estimated percentage of savings recognized | 35% | |||||
Project Pegasus | Fiscal 2026 | ||||||
Restructuring Plan | ||||||
Estimated percentage of savings recognized | 25% | |||||
Project Pegasus | Fiscal 2027 | ||||||
Restructuring Plan | ||||||
Estimated percentage of savings recognized | 15% | |||||
Project Pegasus | Minimum | ||||||
Restructuring Plan | ||||||
Expected restructuring costs | 50,000 | 50,000 | ||||
Annualized profit improvements | 75,000 | |||||
Project Pegasus | Minimum | Home & Outdoor | ||||||
Restructuring Plan | ||||||
Expected restructuring costs | 16,000 | 16,000 | ||||
Project Pegasus | Minimum | Beauty & Wellness | ||||||
Restructuring Plan | ||||||
Expected restructuring costs | 34,000 | 34,000 | ||||
Project Pegasus | Minimum | Severance and employee related costs | ||||||
Restructuring Plan | ||||||
Expected restructuring costs | 15,000 | 15,000 | ||||
Project Pegasus | Minimum | Contract termination | ||||||
Restructuring Plan | ||||||
Expected restructuring costs | 3,000 | 3,000 | ||||
Project Pegasus | Maximum | ||||||
Restructuring Plan | ||||||
Expected restructuring costs | 55,000 | 55,000 | ||||
Annualized profit improvements | $ 85,000 | |||||
Project Pegasus | Maximum | Home & Outdoor | ||||||
Restructuring Plan | ||||||
Expected restructuring costs | 17,000 | 17,000 | ||||
Project Pegasus | Maximum | Beauty & Wellness | ||||||
Restructuring Plan | ||||||
Expected restructuring costs | 38,000 | 38,000 | ||||
Project Pegasus | Maximum | Severance and employee related costs | ||||||
Restructuring Plan | ||||||
Expected restructuring costs | 19,000 | 19,000 | ||||
Project Pegasus | Maximum | Contract termination | ||||||
Restructuring Plan | ||||||
Expected restructuring costs | 4,000 | 4,000 | ||||
Project Pegasus | Maximum | Other | ||||||
Restructuring Plan | ||||||
Expected restructuring costs | $ 4,000 | $ 4,000 |
Restructuring Plan - Restructur
Restructuring Plan - Restructuring Charges to Date (Details) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | 24 Months Ended | ||
Aug. 31, 2024 | Aug. 31, 2023 | Aug. 31, 2024 | Aug. 31, 2023 | May 31, 2024 | |
Restructuring Plan | |||||
Total restructuring charges | $ 1,526 | $ 3,617 | $ 3,361 | $ 10,972 | |
Project Pegasus | |||||
Restructuring Plan | |||||
Severance and employee related costs | 791 | 588 | 2,356 | 1,480 | $ 17,632 |
Professional fees | 583 | 2,901 | 853 | 8,527 | 27,730 |
Contract termination | 0 | 108 | 0 | 796 | 1,331 |
Other | 152 | 20 | 152 | 169 | 2,742 |
Total restructuring charges | 1,526 | 3,617 | 3,361 | 10,972 | $ 49,435 |
Home & Outdoor | Project Pegasus | |||||
Restructuring Plan | |||||
Severance and employee related costs | 250 | 87 | 690 | 571 | |
Professional fees | 268 | 1,182 | 268 | 3,451 | |
Contract termination | 0 | 0 | 0 | 0 | |
Other | 0 | 2 | 0 | 39 | |
Total restructuring charges | 518 | 1,271 | 958 | 4,061 | |
Beauty & Wellness | Project Pegasus | |||||
Restructuring Plan | |||||
Severance and employee related costs | 541 | 501 | 1,666 | 909 | |
Professional fees | 315 | 1,719 | 585 | 5,076 | |
Contract termination | 0 | 108 | 0 | 796 | |
Other | 152 | 18 | 152 | 130 | |
Total restructuring charges | $ 1,008 | $ 2,346 | $ 2,403 | $ 6,911 |
Restructuring Plan - Reserve Ro
Restructuring Plan - Reserve Roll Forward (Details) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | 24 Months Ended | ||
Aug. 31, 2024 | Aug. 31, 2023 | Aug. 31, 2024 | Aug. 31, 2023 | May 31, 2024 | |
Restructuring Reserve [Roll Forward] | |||||
Charges | $ 1,526 | $ 3,617 | $ 3,361 | $ 10,972 | |
Project Pegasus | |||||
Restructuring Reserve [Roll Forward] | |||||
Restructuring liability, beginning balance | 4,765 | 6,568 | |||
Charges | 1,526 | 3,617 | 3,361 | 10,972 | $ 49,435 |
Payments | (5,590) | (15,216) | |||
Restructuring liability, ending balance | 2,536 | 2,324 | 2,536 | 2,324 | |
Severance and employee related costs | Project Pegasus | |||||
Restructuring Reserve [Roll Forward] | |||||
Restructuring liability, beginning balance | 4,493 | 3,173 | |||
Charges | 2,356 | 1,480 | |||
Payments | (4,852) | (3,422) | |||
Restructuring liability, ending balance | 1,997 | 1,231 | 1,997 | 1,231 | |
Professional fees | Project Pegasus | |||||
Restructuring Reserve [Roll Forward] | |||||
Restructuring liability, beginning balance | 272 | 3,201 | |||
Charges | 853 | 8,527 | |||
Payments | (599) | (10,635) | |||
Restructuring liability, ending balance | 526 | 1,093 | 526 | 1,093 | |
Contract termination | Project Pegasus | |||||
Restructuring Reserve [Roll Forward] | |||||
Restructuring liability, beginning balance | 0 | 160 | |||
Charges | 0 | 796 | |||
Payments | 0 | (956) | |||
Restructuring liability, ending balance | 0 | 0 | 0 | 0 | |
Other | Project Pegasus | |||||
Restructuring Reserve [Roll Forward] | |||||
Restructuring liability, beginning balance | 0 | 34 | |||
Charges | 152 | 169 | |||
Payments | (139) | (203) | |||
Restructuring liability, ending balance | $ 13 | $ 0 | $ 13 | $ 0 |
Commitments and Contingencies (
Commitments and Contingencies (Details) | Dec. 23, 2021 renewal |
Commitments and Contingencies Disclosure [Abstract] | |
Number of other companies named in litigation | 5 |
Long-Term Debt - Schedule (Deta
Long-Term Debt - Schedule (Details) - USD ($) $ in Thousands | Aug. 31, 2024 | Feb. 29, 2024 |
Long-term debt | ||
Unamortized prepaid financing fees | $ (5,640) | $ (6,279) |
Total long-term debt | 713,235 | 665,671 |
Less: current maturities of long-term debt | (7,813) | (6,250) |
Long-term debt, excluding current maturities | $ 705,422 | $ 659,421 |
Line of credit | ||
Long-term debt | ||
Weighted average effective interest rate | 6.30% | 6% |
Line of credit | Credit Agreement | ||
Long-term debt | ||
Aggregate principal balance | $ 718,875 | $ 671,950 |
Line of credit | Credit Agreement | Revolving loans | ||
Long-term debt | ||
Aggregate principal balance | 472,000 | 421,950 |
Line of credit | Credit Agreement | Term loans | ||
Long-term debt | ||
Aggregate principal balance | $ 246,875 | $ 250,000 |
Long-Term Debt - Narrative (Det
Long-Term Debt - Narrative (Details) $ in Millions | 3 Months Ended | 6 Months Ended | ||||
Feb. 15, 2024 USD ($) | Aug. 31, 2024 USD ($) | Aug. 31, 2023 USD ($) | Aug. 31, 2024 USD ($) | Aug. 31, 2023 USD ($) | Feb. 29, 2024 USD ($) | |
Debt Instrument [Line Items] | ||||||
Interest costs incurred | $ 13.2 | $ 13.7 | $ 25.8 | $ 28.6 | ||
Interest costs capitalized | 0 | $ 0 | 0 | $ 0.9 | ||
Maximum net leverage ratio | 3.25 | |||||
Term loans | ||||||
Debt Instrument [Line Items] | ||||||
Aggregate principal amount | $ 250 | |||||
Revolving loans | Credit Agreement | ||||||
Debt Instrument [Line Items] | ||||||
Maximum revolving commitment | 1,500 | |||||
Line of credit | ||||||
Debt Instrument [Line Items] | ||||||
Fixed rate debt | 300 | 300 | $ 500 | |||
Maximum additional debt allowed under debt covenants | 322.8 | 322.8 | ||||
Maximum additional debt allowed in the event a qualified acquisition is consummated | 518.5 | 518.5 | ||||
Line of credit | Credit Agreement | ||||||
Debt Instrument [Line Items] | ||||||
Maximum allowable increase due to accordion feature | $ 300 | |||||
Line of credit | Credit Agreement | Minimum | Base rate | Variable Rate Component One | ||||||
Debt Instrument [Line Items] | ||||||
Margin (as a percent) | 0% | |||||
Line of credit | Credit Agreement | Minimum | SOFR | Variable Rate Component Two | ||||||
Debt Instrument [Line Items] | ||||||
Margin (as a percent) | 1% | |||||
Line of credit | Credit Agreement | Maximum | Base rate | Variable Rate Component One | ||||||
Debt Instrument [Line Items] | ||||||
Margin (as a percent) | 1.125% | |||||
Line of credit | Credit Agreement | Maximum | SOFR | Variable Rate Component Two | ||||||
Debt Instrument [Line Items] | ||||||
Margin (as a percent) | 2.125% | |||||
Line of credit | Revolving loans | Credit Agreement | ||||||
Debt Instrument [Line Items] | ||||||
Maximum revolving commitment | $ 1,000 | |||||
Proceeds from revolving credit facility | 457.5 | |||||
Fixed rate debt | 300 | 300 | $ 500 | |||
Amount available for borrowings | 518.5 | 518.5 | ||||
Line of credit | Letter of credit | ||||||
Debt Instrument [Line Items] | ||||||
Amount outstanding, letters of credit | $ 9.5 | $ 9.5 | ||||
Line of credit | Letter of credit | Credit Agreement | ||||||
Debt Instrument [Line Items] | ||||||
Maximum revolving commitment | 50 | |||||
Line of credit | Term loans | Credit Agreement | ||||||
Debt Instrument [Line Items] | ||||||
Proceeds from term loan facility | $ 250 | |||||
Line of credit | Term loans | Credit Agreement | Through February 28, 2025 | ||||||
Debt Instrument [Line Items] | ||||||
Percent of term loans due quarterly | 0.625% | |||||
Line of credit | Term loans | Credit Agreement | Through February 28, 2026 | ||||||
Debt Instrument [Line Items] | ||||||
Percent of term loans due quarterly | 0.9375% | |||||
Line of credit | Term loans | Credit Agreement | After February 28th, 2026 | ||||||
Debt Instrument [Line Items] | ||||||
Percent of term loans due quarterly | 1.25% | |||||
Line of credit | Delayed Draw Term Loan (DDTL) | Credit Agreement | ||||||
Debt Instrument [Line Items] | ||||||
Aggregate principal amount | $ 250 |
Fair Value - Summary of Financi
Fair Value - Summary of Financial Assets and Liabilities (Details) - Recurring - Fair Values - Fair Value, Inputs, Level 2 - USD ($) $ in Thousands | Aug. 31, 2024 | Feb. 29, 2024 |
Assets: | ||
Cash equivalents (money market accounts) | $ 3,275 | $ 462 |
Total assets | 12,888 | 12,506 |
Liabilities: | ||
Total liabilities | 2,289 | 386 |
Interest rate swaps | ||
Assets: | ||
Derivative assets | 0 | 2,504 |
Liabilities: | ||
Derivative liabilities | 788 | 0 |
Foreign currency derivatives | ||
Assets: | ||
Derivative assets | 346 | 592 |
Liabilities: | ||
Derivative liabilities | 1,501 | 386 |
U.S. Treasury Bills | ||
Assets: | ||
U.S. Treasury Bills | $ 9,267 | $ 8,948 |
Fair Value - Narrative (Details
Fair Value - Narrative (Details) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | 12 Months Ended |
Aug. 31, 2024 | Aug. 31, 2024 | Feb. 29, 2024 | |
Fair Value | |||
Investment income, interest | $ 100 | $ 100 | |
U.S. Treasury Bills | |||
Fair Value | |||
Unrealized loss on US Treasury bills | $ (100) | $ 0 | |
U.S. Treasury Bills | Minimum | |||
Fair Value | |||
Term of US treasury bills held to maturity (less than one to five years) | 1 year | 1 year | |
U.S. Treasury Bills | Maximum | |||
Fair Value | |||
Term of US treasury bills held to maturity (less than one to five years) | 5 years | 5 years | |
U.S. Treasury Bills | Prepaid Expenses and Other Current Assets | |||
Fair Value | |||
US treasury bills, carrying value, current | $ 2,500 | $ 2,500 | 2,500 |
U.S. Treasury Bills | Other Assets | |||
Fair Value | |||
US treasury bills, carrying value, non-current | 6,700 | 6,700 | 6,600 |
US treasury bills, carrying value, current | $ 2,500 | $ 2,500 | $ 2,500 |
Financial Instruments and Ris_3
Financial Instruments and Risk Management - Narrative (Details) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | |||
Aug. 31, 2024 | Aug. 31, 2023 | Aug. 31, 2024 | Aug. 31, 2023 | Feb. 29, 2024 | |
Foreign currency derivatives | Cash flow hedges | |||||
Foreign Currency Risk and Currency Exchange Uncertainties | |||||
Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimated Net Amount to be Transferred | $ (1,600) | ||||
Period of reclassification to AOCI | 12 months | ||||
Credit agreement | |||||
Foreign Currency Risk and Currency Exchange Uncertainties | |||||
Fixed rate debt | $ 300,000 | $ 300,000 | $ 500,000 | ||
Credit agreement | Credit Agreement | |||||
Foreign Currency Risk and Currency Exchange Uncertainties | |||||
Aggregate principal balance | 718,875 | 718,875 | $ 671,950 | ||
Income Tax Expense | |||||
Foreign Currency Risk and Currency Exchange Uncertainties | |||||
Net foreign exchange gains (losses), including the impact of currency hedges and currency swaps | $ 200 | $ 200 | 300 | $ 400 | |
SG&A | |||||
Foreign Currency Risk and Currency Exchange Uncertainties | |||||
Net foreign exchange gains (losses), including the impact of currency hedges and currency swaps | $ (800) | $ 600 | $ (400) | ||
Net sales revenue | Geographic concentration | International operations - transactions denominated in foreign currencies | |||||
Foreign Currency Risk and Currency Exchange Uncertainties | |||||
Concentration risk percentage | 12% | 12% | 14% | 14% |
Financial Instruments and Ris_4
Financial Instruments and Risk Management - Derivative FV (Details) € in Thousands, £ in Thousands, kr in Thousands, $ in Thousands, $ in Thousands | Aug. 31, 2024 EUR (€) | Aug. 31, 2024 USD ($) | Aug. 31, 2024 CAD ($) | Aug. 31, 2024 GBP (£) | Aug. 31, 2024 NOK (kr) | Feb. 29, 2024 EUR (€) | Feb. 29, 2024 USD ($) | Feb. 29, 2024 CAD ($) | Feb. 29, 2024 GBP (£) | Feb. 29, 2024 NOK (kr) |
Prepaid Expenses and Other Current Assets | ||||||||||
Fair values of derivative instruments in the consolidated balance sheet | ||||||||||
Derivative assets | $ 297 | $ 1,906 | ||||||||
Other Assets | ||||||||||
Fair values of derivative instruments in the consolidated balance sheet | ||||||||||
Derivative assets | 49 | 1,190 | ||||||||
Accrued Expenses and Other Current Liabilities | ||||||||||
Fair values of derivative instruments in the consolidated balance sheet | ||||||||||
Derivative liabilities | 1,829 | 386 | ||||||||
Other Liabilities, Non- Current | ||||||||||
Fair values of derivative instruments in the consolidated balance sheet | ||||||||||
Derivative liabilities | 460 | 0 | ||||||||
Derivatives designated as hedging instruments | Prepaid Expenses and Other Current Assets | ||||||||||
Fair values of derivative instruments in the consolidated balance sheet | ||||||||||
Derivative assets | 247 | 1,906 | ||||||||
Derivatives designated as hedging instruments | Other Assets | ||||||||||
Fair values of derivative instruments in the consolidated balance sheet | ||||||||||
Derivative assets | 49 | 1,190 | ||||||||
Derivatives designated as hedging instruments | Accrued Expenses and Other Current Liabilities | ||||||||||
Fair values of derivative instruments in the consolidated balance sheet | ||||||||||
Derivative liabilities | 1,829 | 381 | ||||||||
Derivatives designated as hedging instruments | Other Liabilities, Non- Current | ||||||||||
Fair values of derivative instruments in the consolidated balance sheet | ||||||||||
Derivative liabilities | 460 | 0 | ||||||||
Derivatives designated as hedging instruments | Foreign currency derivatives | Sell | ||||||||||
Fair values of derivative instruments in the consolidated balance sheet | ||||||||||
Notional Amount | $ 14,250 | £ 30,800 | kr 16,500 | € 36,500 | $ 20,750 | £ 20,250 | kr 5,000 | |||
Derivatives designated as hedging instruments | Foreign currency derivatives | Sell | Euros | ||||||||||
Fair values of derivative instruments in the consolidated balance sheet | ||||||||||
Notional Amount | € | € 47,500 | |||||||||
Derivatives designated as hedging instruments | Foreign currency derivatives | Sell | Euros | Prepaid Expenses and Other Current Assets | ||||||||||
Fair values of derivative instruments in the consolidated balance sheet | ||||||||||
Derivative assets | 134 | 377 | ||||||||
Derivatives designated as hedging instruments | Foreign currency derivatives | Sell | Euros | Other Assets | ||||||||||
Fair values of derivative instruments in the consolidated balance sheet | ||||||||||
Derivative assets | 46 | 0 | ||||||||
Derivatives designated as hedging instruments | Foreign currency derivatives | Sell | Euros | Accrued Expenses and Other Current Liabilities | ||||||||||
Fair values of derivative instruments in the consolidated balance sheet | ||||||||||
Derivative liabilities | 277 | 90 | ||||||||
Derivatives designated as hedging instruments | Foreign currency derivatives | Sell | Euros | Other Liabilities, Non- Current | ||||||||||
Fair values of derivative instruments in the consolidated balance sheet | ||||||||||
Derivative liabilities | 23 | 0 | ||||||||
Derivatives designated as hedging instruments | Foreign currency derivatives | Sell | Canadian Dollars | Prepaid Expenses and Other Current Assets | ||||||||||
Fair values of derivative instruments in the consolidated balance sheet | ||||||||||
Derivative assets | 82 | 151 | ||||||||
Derivatives designated as hedging instruments | Foreign currency derivatives | Sell | Canadian Dollars | Other Assets | ||||||||||
Fair values of derivative instruments in the consolidated balance sheet | ||||||||||
Derivative assets | 0 | 0 | ||||||||
Derivatives designated as hedging instruments | Foreign currency derivatives | Sell | Canadian Dollars | Accrued Expenses and Other Current Liabilities | ||||||||||
Fair values of derivative instruments in the consolidated balance sheet | ||||||||||
Derivative liabilities | 68 | 57 | ||||||||
Derivatives designated as hedging instruments | Foreign currency derivatives | Sell | Canadian Dollars | Other Liabilities, Non- Current | ||||||||||
Fair values of derivative instruments in the consolidated balance sheet | ||||||||||
Derivative liabilities | 0 | 0 | ||||||||
Derivatives designated as hedging instruments | Foreign currency derivatives | Sell | Pounds | Prepaid Expenses and Other Current Assets | ||||||||||
Fair values of derivative instruments in the consolidated balance sheet | ||||||||||
Derivative assets | 9 | 59 | ||||||||
Derivatives designated as hedging instruments | Foreign currency derivatives | Sell | Pounds | Other Assets | ||||||||||
Fair values of derivative instruments in the consolidated balance sheet | ||||||||||
Derivative assets | 3 | 0 | ||||||||
Derivatives designated as hedging instruments | Foreign currency derivatives | Sell | Pounds | Accrued Expenses and Other Current Liabilities | ||||||||||
Fair values of derivative instruments in the consolidated balance sheet | ||||||||||
Derivative liabilities | 956 | 234 | ||||||||
Derivatives designated as hedging instruments | Foreign currency derivatives | Sell | Pounds | Other Liabilities, Non- Current | ||||||||||
Fair values of derivative instruments in the consolidated balance sheet | ||||||||||
Derivative liabilities | 177 | 0 | ||||||||
Derivatives designated as hedging instruments | Foreign currency derivatives | Sell | Norwegian Kroner | Prepaid Expenses and Other Current Assets | ||||||||||
Fair values of derivative instruments in the consolidated balance sheet | ||||||||||
Derivative assets | 22 | 5 | ||||||||
Derivatives designated as hedging instruments | Foreign currency derivatives | Sell | Norwegian Kroner | Other Assets | ||||||||||
Fair values of derivative instruments in the consolidated balance sheet | ||||||||||
Derivative assets | 0 | 0 | ||||||||
Derivatives designated as hedging instruments | Foreign currency derivatives | Sell | Norwegian Kroner | Accrued Expenses and Other Current Liabilities | ||||||||||
Fair values of derivative instruments in the consolidated balance sheet | ||||||||||
Derivative liabilities | 0 | 0 | ||||||||
Derivatives designated as hedging instruments | Foreign currency derivatives | Sell | Norwegian Kroner | Other Liabilities, Non- Current | ||||||||||
Fair values of derivative instruments in the consolidated balance sheet | ||||||||||
Derivative liabilities | 0 | 0 | ||||||||
Derivatives designated as hedging instruments | Interest rate swaps | ||||||||||
Fair values of derivative instruments in the consolidated balance sheet | ||||||||||
Notional Amount | 300,000 | 500,000 | ||||||||
Derivatives designated as hedging instruments | Interest rate swaps | Prepaid Expenses and Other Current Assets | ||||||||||
Fair values of derivative instruments in the consolidated balance sheet | ||||||||||
Derivative assets | 0 | 1,314 | ||||||||
Derivatives designated as hedging instruments | Interest rate swaps | Other Assets | ||||||||||
Fair values of derivative instruments in the consolidated balance sheet | ||||||||||
Derivative assets | 0 | 1,190 | ||||||||
Derivatives designated as hedging instruments | Interest rate swaps | Accrued Expenses and Other Current Liabilities | ||||||||||
Fair values of derivative instruments in the consolidated balance sheet | ||||||||||
Derivative liabilities | 528 | 0 | ||||||||
Derivatives designated as hedging instruments | Interest rate swaps | Other Liabilities, Non- Current | ||||||||||
Fair values of derivative instruments in the consolidated balance sheet | ||||||||||
Derivative liabilities | 260 | 0 | ||||||||
Derivatives not designated under hedge accounting | Prepaid Expenses and Other Current Assets | ||||||||||
Fair values of derivative instruments in the consolidated balance sheet | ||||||||||
Derivative assets | 50 | 0 | ||||||||
Derivatives not designated under hedge accounting | Other Assets | ||||||||||
Fair values of derivative instruments in the consolidated balance sheet | ||||||||||
Derivative assets | 0 | 0 | ||||||||
Derivatives not designated under hedge accounting | Accrued Expenses and Other Current Liabilities | ||||||||||
Fair values of derivative instruments in the consolidated balance sheet | ||||||||||
Derivative liabilities | 0 | 5 | ||||||||
Derivatives not designated under hedge accounting | Other Liabilities, Non- Current | ||||||||||
Fair values of derivative instruments in the consolidated balance sheet | ||||||||||
Derivative liabilities | 0 | 0 | ||||||||
Derivatives not designated under hedge accounting | Foreign currency derivatives | Euros | Prepaid Expenses and Other Current Assets | ||||||||||
Fair values of derivative instruments in the consolidated balance sheet | ||||||||||
Derivative assets | 0 | |||||||||
Derivatives not designated under hedge accounting | Foreign currency derivatives | Euros | Other Assets | ||||||||||
Fair values of derivative instruments in the consolidated balance sheet | ||||||||||
Derivative assets | 0 | |||||||||
Derivatives not designated under hedge accounting | Foreign currency derivatives | Euros | Accrued Expenses and Other Current Liabilities | ||||||||||
Fair values of derivative instruments in the consolidated balance sheet | ||||||||||
Derivative liabilities | 3 | |||||||||
Derivatives not designated under hedge accounting | Foreign currency derivatives | Euros | Other Liabilities, Non- Current | ||||||||||
Fair values of derivative instruments in the consolidated balance sheet | ||||||||||
Derivative liabilities | 0 | |||||||||
Derivatives not designated under hedge accounting | Foreign currency derivatives | Pounds | Prepaid Expenses and Other Current Assets | ||||||||||
Fair values of derivative instruments in the consolidated balance sheet | ||||||||||
Derivative assets | 0 | |||||||||
Derivatives not designated under hedge accounting | Foreign currency derivatives | Pounds | Other Assets | ||||||||||
Fair values of derivative instruments in the consolidated balance sheet | ||||||||||
Derivative assets | 0 | |||||||||
Derivatives not designated under hedge accounting | Foreign currency derivatives | Pounds | Accrued Expenses and Other Current Liabilities | ||||||||||
Fair values of derivative instruments in the consolidated balance sheet | ||||||||||
Derivative liabilities | 2 | |||||||||
Derivatives not designated under hedge accounting | Foreign currency derivatives | Pounds | Other Liabilities, Non- Current | ||||||||||
Fair values of derivative instruments in the consolidated balance sheet | ||||||||||
Derivative liabilities | $ 0 | |||||||||
Derivatives not designated under hedge accounting | Cross currency debt swaps | ||||||||||
Fair values of derivative instruments in the consolidated balance sheet | ||||||||||
Notional Amount | € 2,450 | £ 790 | € 430 | £ 735 | ||||||
Derivatives not designated under hedge accounting | Cross currency debt swaps | Euros | Prepaid Expenses and Other Current Assets | ||||||||||
Fair values of derivative instruments in the consolidated balance sheet | ||||||||||
Derivative assets | 23 | |||||||||
Derivatives not designated under hedge accounting | Cross currency debt swaps | Euros | Other Assets | ||||||||||
Fair values of derivative instruments in the consolidated balance sheet | ||||||||||
Derivative assets | 0 | |||||||||
Derivatives not designated under hedge accounting | Cross currency debt swaps | Euros | Accrued Expenses and Other Current Liabilities | ||||||||||
Fair values of derivative instruments in the consolidated balance sheet | ||||||||||
Derivative liabilities | 0 | |||||||||
Derivatives not designated under hedge accounting | Cross currency debt swaps | Euros | Other Liabilities, Non- Current | ||||||||||
Fair values of derivative instruments in the consolidated balance sheet | ||||||||||
Derivative liabilities | 0 | |||||||||
Derivatives not designated under hedge accounting | Cross currency debt swaps | Pounds | Prepaid Expenses and Other Current Assets | ||||||||||
Fair values of derivative instruments in the consolidated balance sheet | ||||||||||
Derivative assets | 27 | |||||||||
Derivatives not designated under hedge accounting | Cross currency debt swaps | Pounds | Other Assets | ||||||||||
Fair values of derivative instruments in the consolidated balance sheet | ||||||||||
Derivative assets | 0 | |||||||||
Derivatives not designated under hedge accounting | Cross currency debt swaps | Pounds | Accrued Expenses and Other Current Liabilities | ||||||||||
Fair values of derivative instruments in the consolidated balance sheet | ||||||||||
Derivative liabilities | 0 | |||||||||
Derivatives not designated under hedge accounting | Cross currency debt swaps | Pounds | Other Liabilities, Non- Current | ||||||||||
Fair values of derivative instruments in the consolidated balance sheet | ||||||||||
Derivative liabilities | $ 0 |
Financial Instruments and Ris_5
Financial Instruments and Risk Management - Derivative Tax Effect (Details) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | ||
Aug. 31, 2024 | Aug. 31, 2023 | Aug. 31, 2024 | Aug. 31, 2023 | |
Pre-tax effect of derivative instruments | ||||
Gain (Loss) Recognized in AOCI | $ (4,852) | $ 4,865 | $ (2,668) | $ 1,764 |
Gain (Loss) Reclassified from AOCI into Income | 772 | 1,644 | 2,040 | 3,389 |
Gain (Loss) Recognized in Income | 66 | (16) | 88 | (40) |
Foreign currency derivatives | Cash flow hedges | ||||
Pre-tax effect of derivative instruments | ||||
Gain (Loss) Recognized in AOCI | (1,317) | (779) | (1,425) | (1,246) |
Foreign currency derivatives | Cash flow hedges | SG&A | ||||
Pre-tax effect of derivative instruments | ||||
Gain (Loss) Reclassified from AOCI into Income | (193) | (383) | (9) | (45) |
Interest rate swaps | Cash flow hedges | ||||
Pre-tax effect of derivative instruments | ||||
Gain (Loss) Recognized in AOCI | (3,535) | 5,644 | (1,243) | 3,010 |
Interest rate swaps | Cash flow hedges | Interest expense | ||||
Pre-tax effect of derivative instruments | ||||
Gain (Loss) Reclassified from AOCI into Income | 965 | 2,027 | 2,049 | 3,434 |
Forward contracts | SG&A | ||||
Pre-tax effect of derivative instruments | ||||
Gain (Loss) Recognized in Income | $ 66 | $ (16) | $ 88 | $ (40) |
Accumulated Other Comprehensi_3
Accumulated Other Comprehensive Income (Loss) (Details) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | ||||
Aug. 31, 2024 | May 31, 2024 | Aug. 31, 2023 | May 31, 2023 | Aug. 31, 2024 | Aug. 31, 2023 | |
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward] | ||||||
Beginning balance | $ 1,549,500 | $ 1,637,442 | $ 1,514,908 | $ 1,488,811 | $ 1,637,442 | $ 1,488,811 |
Other comprehensive loss before reclassification | (2,668) | 1,764 | ||||
Amounts reclassified out of AOCI | (2,040) | (3,389) | ||||
Tax effects | 1,094 | 364 | ||||
Total other comprehensive (loss) income, net of tax | (4,312) | 698 | 2,454 | (3,715) | (3,614) | (1,261) |
Ending balance | 1,567,580 | 1,549,500 | 1,501,883 | 1,514,908 | 1,567,580 | 1,501,883 |
Interest Rate Swaps | ||||||
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward] | ||||||
Beginning balance | 1,917 | 4,394 | 1,917 | 4,394 | ||
Other comprehensive loss before reclassification | (1,243) | 3,010 | ||||
Amounts reclassified out of AOCI | (2,049) | (3,434) | ||||
Tax effects | 771 | 100 | ||||
Total other comprehensive (loss) income, net of tax | (2,521) | (324) | ||||
Ending balance | (604) | 4,070 | (604) | 4,070 | ||
Foreign Currency Contracts | ||||||
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward] | ||||||
Beginning balance | 182 | 553 | 182 | 553 | ||
Other comprehensive loss before reclassification | (1,425) | (1,246) | ||||
Amounts reclassified out of AOCI | 9 | 45 | ||||
Tax effects | 323 | 264 | ||||
Total other comprehensive (loss) income, net of tax | (1,093) | (937) | ||||
Ending balance | (911) | (384) | (911) | (384) | ||
Total | ||||||
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward] | ||||||
Beginning balance | 2,797 | 2,099 | 1,232 | 4,947 | 2,099 | 4,947 |
Total other comprehensive (loss) income, net of tax | (4,312) | 698 | 2,454 | (3,715) | ||
Ending balance | $ (1,515) | $ 2,797 | $ 3,686 | $ 1,232 | $ (1,515) | $ 3,686 |
Segment and Geographic Inform_3
Segment and Geographic Information - Segment Information by Segment (Details) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | ||
Aug. 31, 2024 | Aug. 31, 2023 | Aug. 31, 2024 | Aug. 31, 2023 | |
Segment information | ||||
Sales revenue, net | $ 474,221 | $ 491,563 | $ 891,068 | $ 966,235 |
Restructuring charges | 1,526 | 3,617 | 3,361 | 10,972 |
Operating income | 34,852 | 46,845 | 65,615 | 87,486 |
Capital and intangible asset expenditures | 14,026 | 20,557 | ||
Depreciation and amortization | 27,628 | 24,606 | ||
Operating Segments | ||||
Segment information | ||||
Sales revenue, net | 474,221 | 491,563 | 891,068 | 966,235 |
Restructuring charges | 1,526 | 3,617 | 3,361 | 10,972 |
Operating income | 34,852 | 46,845 | 65,615 | 87,486 |
Capital and intangible asset expenditures | 4,884 | 8,680 | 14,026 | 20,557 |
Depreciation and amortization | 13,792 | 13,891 | 27,628 | 24,606 |
Home & Outdoor | Operating Segments | ||||
Segment information | ||||
Sales revenue, net | 241,944 | 239,977 | 440,403 | 457,121 |
Restructuring charges | 518 | 1,271 | 958 | 4,061 |
Operating income | 31,152 | 36,099 | 47,002 | 58,215 |
Capital and intangible asset expenditures | 1,722 | 4,879 | 7,467 | 15,839 |
Depreciation and amortization | 6,590 | 6,606 | 13,237 | 11,008 |
Beauty & Wellness | Operating Segments | ||||
Segment information | ||||
Sales revenue, net | 232,277 | 251,586 | 450,665 | 509,114 |
Restructuring charges | 1,008 | 2,346 | 2,403 | 6,911 |
Operating income | 3,700 | 10,746 | 18,613 | 29,271 |
Capital and intangible asset expenditures | 3,162 | 3,801 | 6,559 | 4,718 |
Depreciation and amortization | $ 7,202 | $ 7,285 | $ 14,391 | $ 13,598 |
Segment and Geographic Inform_4
Segment and Geographic Information - Revenue by Domestic and International (Details) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | ||
Aug. 31, 2024 | Aug. 31, 2023 | Aug. 31, 2024 | Aug. 31, 2023 | |
Segment information | ||||
Sales revenue, net | $ 474,221 | $ 491,563 | $ 891,068 | $ 966,235 |
Domestic sales revenue, net | ||||
Segment information | ||||
Sales revenue, net | 365,750 | 388,049 | 666,430 | 747,608 |
International sales revenue, net | ||||
Segment information | ||||
Sales revenue, net | $ 108,471 | $ 103,514 | $ 224,638 | $ 218,627 |
Revenue from Contract with Customer Benchmark | Geographic concentration | ||||
Segment information | ||||
Concentration risk percentage | 100% | 100% | 100% | 100% |
Revenue from Contract with Customer Benchmark | Geographic concentration | Domestic sales revenue, net | ||||
Segment information | ||||
Concentration risk percentage | 77.10% | 78.90% | 74.80% | 77.40% |
Revenue from Contract with Customer Benchmark | Geographic concentration | International sales revenue, net | ||||
Segment information | ||||
Concentration risk percentage | 22.90% | 21.10% | 25.20% | 22.60% |
Income Taxes (Details)
Income Taxes (Details) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended | ||
Aug. 31, 2024 | Aug. 31, 2023 | Aug. 31, 2024 | Aug. 31, 2023 | |
Effective Income Tax Rate Reconciliation [Line Items] | ||||
Income tax expense (benefit) as a percent of income before income taxes | 22% | 17.90% | 42.10% | 16.80% |
Foreign Tax Authority | Barbados Revenue Authority | ||||
Effective Income Tax Rate Reconciliation [Line Items] | ||||
Discrete tax charge due to change in legislation | $ 6 | $ 6 |
Earnings per Share (Details)
Earnings per Share (Details) - shares shares in Thousands | 3 Months Ended | 6 Months Ended | ||
Aug. 31, 2024 | Aug. 31, 2023 | Aug. 31, 2024 | Aug. 31, 2023 | |
Weighted average diluted securities | ||||
Weighted average shares outstanding, basic (in shares) | 22,814 | 23,918 | 23,169 | 23,984 |
Incremental shares from share-based payment arrangements (in shares) | 25 | 123 | 67 | 104 |
Weighted average shares outstanding, diluted (in shares) | 22,839 | 24,041 | 23,236 | 24,088 |
Anti-dilutive securities | ||||
Weighted average diluted securities | ||||
Antidilutive securities (in shares) | 155 | 7 | 140 | 81 |